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Dankwoord 
 
Een doctoraat is als een lange bergwandeling: met veel hindernissen, veel dieptepunten, 
maar ook veel hoogtepunten en veel voldoening als het einde is bereikt. Het is een heel 
leerrijke ervaring geworden, zowel op professioneel als op persoonlijk vlak. Het is me echter 
enkel gelukt door de vele steun die ik heb gekregen, maar ook door het plezier dat ik vond 
en de energie die ik kreeg tijdens de leuke momentjes die we hebben gedeeld. Ik wil dan ook 
graag een aantal mensen bedanken. 
Eerst en vooral wil ik mijn promotor Professor Wim Robberecht van harte danken om me de 
kans te geven deel te maken van zijn onderzoeksteam. Ik apprecieerde heel erg uw 
opmerkingen en suggesties en alle discussies die me de data terug vanuit een ander 
perspectief deden bekijken. U slaagde er ook steeds in om me aan te moedigen als ik het 
even niet meer zag zitten en om mijn enthousiasme te temperen als ik wat te veel in de 
wolken was met mijn data. Ik heb ook heel veel geleerd van uw manier om alles uit te 
leggen, zowel mondeling als geschreven. Ook wil ik u bedanken voor uw extra begrip en 
geduld tijdens mijn eerste doctoraatsjaar.  
Mijn co-promotoren Professor Robin Lemmens en Professor Philip Van Damme wil ik graag 
bedanken voor de dagelijkse begeleiding. U stond altijd klaar als ik iets wilde bespreken of 
om mij goede raad te geven. Robin, heel erg bedankt voor alle hulp tijdens de laatste 
eindsprint. Ik apprecieerde het heel erg dat u steeds tijd voor me vrij maakte, zelfs tijdens 
heel hectische periodes. Philip, dank u voor de leuke discussies, die terug ander licht op de 
resultaten konden werpen. Uw rustige, kalme uitstraling tijdens presentaties op 
internationale conferenties en tijdens drukke momenten zijn bewonderenswaardig. Ook wil 
ik graag Professor Ludo Van den Bosch bedanken om me steeds verder te helpen. Uw deur 
stond steeds voor mij open voor zowel de wetenschappelijke als de praktische zaken.  
Special thanks to the members of my jury, Professor Albert Ludolph, Professor Serge 
Muyldermans, Professor Patrik Verstreken, Professor Mieke Dewerchin and Professor 
Matthew Holt for their thorough and critical reading of my thesis manuscript. Your 
comments and suggestions really improved the quality of my thesis.  
I am also very grateful of all the very nice collaborations. Professor Ann Van Schepdael, 
bedankt voor de prettige samenwerking i.v.m. de HPLC-analyse van C1. Bart, dank je wel om 
me op de goede weg te zetten met mijn Nanobody screen en voor de leuke samenwerking 
betreffende de SPR-data. Ik heb het altijd heel erg geapprecieerd dat je alles heel grondig 
hebt uitgelegd en dat ik altijd bij je terecht kon voor extra uitleg. Jurgen and Reza, thank you 
for the nice collaboration concerning the generation, production and purification of EphA4 
and my Nanobodies. Annerieke, om me aan heel veel verschillende mensen voor te stellen. 
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Lucia, you really helped me a lot with the Alphascreen and all my biochemical questions. 
Sarah V. en Hermien, om me met vele kleine praktische zaken verder te helpen. Maarten, 
om me wegwijs te maken in de nummering van de Nanobodies en om me te helpen bij het 
solliciteren. Michal, Mykhailo and Chen, thank you for all the help with astrocyte isolation 
and astrocyte problems. Thomas, our nice talks in the animal lab have lead to a nice and 
successful collaboration.   
Ik wil graag al mijn collega’s bedanken voor de leuke tijd in het lab. Bedankt voor de steun in 
moeilijke momenten, de oppeppende woorden als de resultaten tegenvielen, maar ook voor 
al het gelach. Ook wil ik nog eens iedereen bedanken die me heeft geholpen bij de laatste 
eindsprint. Zonder al die hulplijnen zou het nog veel moeilijker geweest zijn.  
De “oude garde” van het labo die me wegwijs heeft gemaakt in het labo, maar die 
ondertussen een andere weg ingeslagen hebben:  Annelies V., Bea, Cindy, Hoai, Veerle C., 
Veerle G., Nicky, Sara, Ines, Thomas, Kim, Sarah H., Sarah D., Constantin, Louis en Elke K., 
Annelies V., om me wegwijs te maken in het efrineproject. Je hebt een fantastisch project 
opgestart en ik vond het heel leuk om dit verder te kunnen uitwerken. Thomas, jouw tips 
i.v.m. kleuringen en microscopie hebben me heel goed geholpen.  
En natuurlijk wil ik ook de huidige mensen in het labo bedanken, beginnende bij het 
fantastische efrine-team. Mieke, ik vond het altijd heel leuk om samen te werken: je 
precieze manier van werken, je neiging alles dubbel te “sjekken”, de prettige samenwerking 
om de Alphascreen te optimaliseren en de leuke babbels over Sieme en Lore. Je kon het 
presteren om steeds afwezig te zijn bij mijn presentaties of stiekem naar de keuken te 
vluchten. Lindsay, ik vond het heel leuk om je wegwijs te maken in het labo. Het was altijd 
heel prettig om samen te werken, toch totdat je in afzondering ging in de kelder. En ik denk 
dat ik na mijn doctoraatsverdediging die langverwachte pisco sour nu wel verdiend heb. 
Laura R., it is really nice that you are always prepared to help people and that you see the 
best in them. It was nice to work together and I’m confident you will finish my project in the 
best way possible. Antina, hoewel je in het begin wat problemen had om me te begrijpen, 
vond ik het altijd heel gemakkelijk om met je te praten. Het was leuk om samen een aantal 
projectjes op te starten en van onze uitstapjes samen kon ik heel erg genieten. Hoewel je 
met zo’n grote bos blonde krullen wel direct in het oog springt, wat ook de mensen van 
Sporza niet was ontgaan.  
Nathalie, het was leuk om samen aan ons doctoraat te starten en samen heel wat watertjes 
te doorzwemmen. Je stond altijd klaar om iedereen te helpen en er kwam dikwijls heel wat 
schatergelach uit het vliegenlabo. Wendy, bedankt voor de fanastische celculturen en voor 
je luisterend oor. Ook van onze shoppinguitjes heb ik heel erg genoten. Veronick, ik vond het 
heel verrijkend om mijn laatste onbegrijpbare resultaten eens te bespreken met mijn 
achterbuur. Gelukkig waren er de wekelijkse squashpartijtjes, een ideale manier om de 
frustraties kwijt te geraken. Ik heb ook enorm genoten van onze tripjes samen, van Portugal 
tot Keulen. Caroline, bedankt voor de leuke gesprekken en pittige wetenschappelijke 
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discussies. Je hebt me toch dikwijls een stapje verder geholpen toen ik vast zat. En ik wist 
ook altijd waar ik moest zijn wanneer mijn schaar en Pritt weer eens zoek waren geraakt. 
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Elke B., bedankt om me steeds verder te helpen als ik de bomen niet meer door het bos zag. 
Cathy, thank you for helping me with Nanobody and writing issues. Steven, buurman, jouw 
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ontploffende thermoskannen, scheefgedraaide kranen, maar ook een gouden hart blijven 
toch jouw kenmerken. André, nobody will ever be able to perform the gangnam style like 
you did. Eveliina, you are the best dishwasher user ever. Raheem, Lore, Laura F. and 
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Matthieu, bedankt voor alle hulp bij de eindsprint. Jolien, door al je goede raad weet ik nu 
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also near for both of you. Good luck! Emiel, Mathias, Annet, Kristof and Joni, veel succes met 
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Maar dit doctoraat was niet mogelijk zonder de steun van mijn familie en vrienden. Lien, 
samen hebben we al veel eindes en nieuwe beginnen meegemaakt. Ik ben blij dat je er ook 
vandaag bij bent. Greet en Lot, jullie stonden er toen ik het moeilijk had en zijn er nu bij deze 
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Hoewel we elkaar niet zo dikwijls zien, weet ik dat jullie er altijd zijn. Elisa and Gian Luca, it’s 
really nice of both of you to come all the way from Italy for my defence. We had a great time 
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Jonas, hoewel je er niet meer bent, weet ik dat je trots op me zou zijn. Mama en papa, 
zonder jullie steun zou ik nu niet staan waar ik nu sta. Lieve zus, samen staan we sterk! Dank 
je om er altijd voor me te zijn. Jille, ik ben blij dat je deel uit maakt van onze familie. Mijn 
lieve, kleine vriend: mijn metekindje Sieme om met je enthousiasme en dikke knuffels steeds 
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Introduction 
 
1. Amyotrophic Lateral Sclerosis  
  
Neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and 
Amyotrophic Lateral Sclerosis (ALS) represent a major challenge for the medical world and 
for society. Even though ALS is a rather rare disease with an incidence of 1-2 in 100.000, the 
life time chance to develop this disease is 1/400 – 1/700 1.  
  
 ALS is a very dramatic disorder due to its progressive character, the short survival of the 
patient and the enormous impact on his/her quality of life and that of his/her caretaker. The 
disease typically affects adults in mid-life and is usually fatal three to five years after the first 
symptoms appear 2-3. It is characterized by the degeneration of both the upper motor 
neurons in the motor cortex, and the lower motor neurons in the brain stem and the spinal 
cord 1. Degeneration of the upper motor neurons leads to spasticity and hyperreflexia, 
whereas degeneration of the lower motor neurons leads to muscle atrophy and eventually 
paralysis. Up to now no curative treatment is available, only riluzole modestly extends 
lifespan with an average of 2-3 months 4-5.  
 
ALS forms a continuum with Frontotemporal Dementia (FTD), with pure ALS and pure FTD on 
the opposites of the spectrum 2. FTD is characterized by neuronal loss in the frontal and 
anterior temporal lobes 6. The most common symptoms are behavior changes, loss of fluent 
speech and loss of the knowledge of words. In the ALS-FTD spectrum many patients have 
features of both. A clinical overlap between both diseases has already been known for 
several decades. The overlap was recently confirmed at the molecular level and underscored 
with neuropathological and genetic studies.   
 
 
1.1 ALS genetics  
 
ALS is hereditary in 10% of patients (familial ALS, FALS), while 90% of patients do not report 
any familial occurrence (sporadic ALS, SALS). Most mutations identified so far are inherited 
in an autosomal dominant way, although autosomal recessive and X-linked inheritance has 
been observed. The most common genes in which mutations have been found are SOD1, 
FUS, TARDBP and C9Orf72 7.  
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1.1.1 Causative genes  
 
Mutations in the superoxide dismutase 1 (SOD1) gene were the first that have been 
identified in ALS 8. SOD1 protects the cell against oxidative stress by converting superoxide 
radicals into molecular oxygen and hydrogen peroxide. The identification of mutations in 
SOD1 led to the development of several mutant SOD1 animal models. The mutant SOD1G93A 
mouse model, overexpressing the human SOD1 gene with a substitution of Glycine by 
Alanine at position 93, is one of the most frequently used models in ALS research 9. The mice 
are asymptomatic until 60 days of age, a time point at which microgliosis can be observed, 
followed by astrogliosis around 80 days. Disease onset occurs around day 90-100 and is 
characterized by massive loss of motor neurons. At this symptomatic stage, initial symptoms 
such as hind limb weakness and tremelous movements can be observed. At late-
symptomatic stage (around 140 days) major symptoms such as progressive atrophy of hind 
limb muscles and paralysis can be observed. Around day 150-160 the mice die preceded by 
disability of gait, eating and drinking 9-10. Overall, mice overexpressing mutant human SOD1 
show similar pathological hallmarks (motor neuron degeneration, inflammation, gliosis and 
paralysis) as seen in ALS patients, while control mice overexpressing wild type human SOD1 
only yield a mild phenotype late in life 9, 11. Furthermore, SOD1 knockout mice do not show 
any sign of motor neuron degeneration, implying a toxic gain of function for mutant SOD1 12. 
Overexpression of mutant human SOD1 in zebrafish embryos induces an axonal phenotype, 
characterized by a reduction of the axonal length and more aberrantly branched axons 13.  
 
The mutant SOD1 mouse is the best ALS model there currently is. It is the most studied 
animal model so far and is widely used in genetic and pharmacological studies worldwide. 
Alike every model, it has its drawbacks, which should be kept in mind when interpreting the 
results obtained with it. This animal will be used in the experiments described later.  
 
In 2008, mutations in TAR DNA binding protein 43 (TDP43, encoded by TARDBP) and Fused in 
Sarcoma/translocated in liposarcoma (FUS/TLS) were identified. TDP43 and FUS are both 
RNA binding proteins with functions in transcription, RNA splicing and RNA transport 14-15. 
Interestingly, aggregates containing TDP43 and FUS are found in patients with SALS 16-17. 
Several animal models have been generated to study the function of TDP43 and FUS. 
However, the use of these models to study ALS needs to be awaited. Homozygous deletion 
of TARDBP or FUS in mice is embryonically lethal, whereas overexpression of the wild type or 
the mutant protein results in a very aggressive phenotype 18. This indicates that both 
depletion as well as overexpression of these proteins is detrimental and highlights the 
necessity of tight regulated TDP43 and FUS expression 19.   
 
Recently, hexanucleotide repeat expansions have been discovered in the first intron of the 
C9Orf72 gene 20-21. The identification of this expansion mutation explains approximately 50% 
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of the familial ALS patients in the Belgian population 22. Furthermore it also accounts for 
more than 5% of apparently sporadic ALS cases. The biological function of the C9Orf72 
protein is still unknown, but several mechanisms of toxicity of the expansion mutation have 
been suggested. One is haploinsufficiency as decreased expression of different C9Orf72 
transcripts has been reported in C9FTD/ALS cases 23. A second is direct RNA toxicity, as the 
hexanucleotide repeat RNA can form highly stable RNA G-quadruplexes, which may 
sequester RNA-binding proteins leading to disruption of RNA metabolism 24-25. A third 
possible mechanism is the production of dipeptide repeat (DPR) proteins from the 
hexanucleotide repeat through repeat-associated non-ATG (RAN) protein translation 26. The 
relative contribution of each of these possible mechanisms in the disease pathogenesis of 
C9-related ALS is under investigation.  
  
Many other genes have been identified in ALS, although most of these mutations have only 
been detected in a limited number of cases or within one family 27.  
 
 
1.1.2   Modifying genes  
 
Age at disease onset, disease duration and the clinical manifestation of ALS (bulbar onset 
versus spinal onset, proximal versus distal weakness) can vary greatly between patients 2. 
Even within one family carrying the same mutation, obvious variability is present 28. This 
indicates that ALS is a multifactorial disease influenced by modifying genes and/or 
environmental factors. Of the latter, none has been identified convincingly 29.  
    
Generally spoken, genetic modifiers can be identified in two ways. Genome-wide association 
studies (GWAS) have identified several disease modifying genes, but not all of results have 
been replicated. The modifying genes that have been confirmed in independent GWAS 
studies are ELP3 (elongator acetyltransferase complex subunit 3), UNC13A (unc-13 homolog 
A) and DPP6 (dipeptidyl-peptidase 6) 30-31. A second way to identify modifiers is through the 
screening of small animal models for ALS, such as Drosophila, yeast and zebrafish. We here 
mention only two results that have been connected to human disease.  
 
An unbiased genetic screen in the TDP43 yeast model revealed that overexpression of 
ataxin2 aggravates the phenotype 32. In Drosophila, upregulation of ataxin2 decreased 
survival of TDP43 flies. In humans, intermediate-length polyglutamine expansions in the 
ataxin2 gene are associated with an increased risk to develop ALS, suggesting the 
importance of this gene in the pathogenesis of ALS 33-34.   
 In our laboratory a morpholino-based genetic screen was performed in the mutant-SOD1 
zebrafish model 35. Knockdown of the ephrin receptor A4 (EphA4) rescued the axonal 
phenotype, a finding confirmed in the ALS mouse model 35. In humans, EphA4 expression is 
inversely correlated with disease onset and disease survival in sporadic ALS patients 35.    
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These results show that the screening of small animal models allows to identify factors that 
also matter for human disease. It is important to identify such factors, as they may be 
targets for intervention, in particular in those forms of the disease in which we do not know 
the cause of disease (yet).    
 
 
1.2 Pathogenesis  
 
Although many hypotheses have been generated, it is still not know what the exact 
mechanism of the selective motor neuron degeneration in ALS is. It is generally accepted 
that it is probably a combination of different ones 19. We here summarize the main 
hypotheses. 
 
1.2.1 Disrupted RNA and protein homeostasis   
 
In ALS, both RNA homeostasis and protein homeostasis are disrupted 36. TDP43 and FUS, 
both RNA-binding proteins involved in multiple RNA processing steps, are major components 
present in pathological inclusions in ALS patients. The formation of TDP43 and FUS 
aggregates has been related to the biology of stress granules. In normal conditions the 
formation of such granules is a reversible process 37. In ALS, these granules apparently do 
not resolve, but form the seeds of aggregation, acting as a sink for proteins, among which 
RNA binding proteins 38. TDP43 and FUS contain low complexity domains that make them 
prone to aggregation and can act to recruit other proteins 39-42. These proteins are thus 
prevented from exerting their normal function and might sequester other essential cellular 
components, which may contribute to cellular dysfunction. This suggests that alterations of 
RNA metabolism are involved in the pathogenesis of ALS 36.  
 
SOD1 on the other hand, is also present in aggregates, but is not involved in stress granule 
formation. To explain its toxicity, it has been suggested that the mutant SOD1 is misfolded 
just as is the demetallated wild type SOD1 43, is aggregation-prone, and forms multimers and 
eventually aggregates.   
 It is thought that these protein multimers overload the normal protein degradation systems 
(the proteasome and the autophagy-lysosomal pathway), which normally protect the cell 
from dysfunctional and degraded proteins and thus from protein aggregation. This 
dysproteostasis leads to further multimerisation and finally protein aggregation. The 
unfolded protein response is an attempt to restore homeostasis, but when unsuccessful, it 
may contribute to the triggering of cell death. The presence of ubiquitin and p62 in 
aggregates and the upregulation of UPR (Unfolded Protein Response) genes in vulnerable 
motor neurons are indicative for such sequence of events 44-45.  
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1.2.2 Glutamate-mediated excitotoxicity  
 
Motor neurons in the spinal cord receive glutamatergic afferents. Glutamate receptors are 
subdivided in ionotropic receptors (ligand-gated cation channels) and metabotropic 
receptors (linked to G-protein coupled receptors). The ionotropic receptors can be further 
divided into three classes, based upon their pharmacological properties: AMPA (α-amino-
hydroxy-5-methyl-4-isoxazole propionic acid), NMDA (N-methyl-D-aspartate) and kainate 
receptors 46-47. AMPA receptors mediate fast excitatory transmission and NMDA receptors 
mediate the late component of excitatory transmission. The excitatory transmission is 
terminated by glutamate removal from the synaptic cleft by glutamate transporter proteins 
in neurons and astrocytes. The most important astrocytic glutamate transporter is Excitatory 
Amino-Acid Transporter 2 (EAAT2/GLT1) 48-49.    
 
Stimulation of ionotropic glutamate receptors induces calcium entry. The intracellular 
calcium levels are tightly controlled by calcium-binding proteins, mitochondria and the 
endoplasmic reticulum (ER) 50-51. When the calcium storage capacity is saturated, 
intracellular calcium levels rise, which can induce neuronal death 52. Motor neurons are very 
sensitive to this phenomenon, called glutamate-mediated excitotoxicity because of their low 
calcium buffering capacity and because of the high calcium permeability of their AMPA 
receptors. The latter is explained by the fact that motor neurons express little glutamate 
receptor 2 subunit (GluR2), which renders the AMPA receptors less permeable to calcium 53. 
In addition to this, EAAT2 expression is decreased in ALS, which results in increased synaptic 
glutamate concentrations 54-58. The only drug that has been shown to affect disease course 
in ALS patients, is riluzole. It is thought, but unproven, that this drug works through its 
glutamate receptor blocking activity 5.   
 
1.2.3 Selective vulnerability of motor neurons  
 
It is unclear why motor neurons are selectively affected in ALS, but some mechanisms that 
may at least partially explain their vulnerability have been suggested. Motor neurons are 
very sensitive to excitotoxicity due to their low expression of calcium buffering proteins and 
of the GluR2 subunit of AMPA receptors, as explained above 59-60. Furthermore, motor 
neurons are very large cells with a somatic diameter of up to 100 µm and axons up to one 
meter long. The high energy demand and metabolic rate of such large cells, and the high 
level of mitochondrial activity with the possible generation of oxidative stress that is 
associated with it, has been suggested to be a vulnerability factor 61. A third vulnerability 
factor is the high threshold for the induction of the stress response, including the activation 
of heat shock protein 70 (Hsp70), compared to other types of neurons 62. Heat shock 
proteins protect neuronal cells against stress such as oxidative stress and excitotoxicity 62-65. 
Overexpression of Hsp70 in motor neurons delayed mutant SOD1 mediated formation of 
aggregates and cell toxicity 66.   
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Interestingly, not all motor neurons are equally vulnerable. There appear to be 
subpopulations of neurons that are less vulnerable. Oculomotor neurons (generating the 
oculomotor, trochlear and abducens nerve controlling eye movement) and neurons in 
Onuf’s nucleus (controlling sphincter muscles) are more resistant to neurodegeneration as 
they are preserved until the very late stages of disease both in ALS patients as in the SOD1 
mouse model 67-70.  
Transcription profile analysis of resistant and vulnerable motor neurons revealed differential 
expression of genes involved in synaptic transmission, ubiquitin-mediated protein 
degradation, mitochondrial function, transcriptional regulation, immune system functions 
and the extracellular matrix, both in rodents as in humans 71. The resistant motor neurons 
show higher expression of the protective AMPA receptor subunit GluR2 and gamma-
aminobutyric acid (GABA) receptor subunit GABAARα1, both involved in synaptic 
transmission 72. Those motor neurons also have increased expression of genes involved in 
mitochondrial oxidative phosphorylation, leading to higher calcium buffering capacity 73. The 
vulnerable motor neurons show higher expression of Matrix metalloproteinase 9 (MMP9) 71. 
In wild type mice MMP9 is only expressed by the vulnerable motor neurons and inhibition of 
its activity in the mutant SOD1 mice delayed muscle denervation 74. Expression of MMP9 in 
the presence of mutant SOD1 enhanced the activation of the UPR thereby triggering axonal 
dieback.   
 
Motor neurons with different physiological characteristics are also differentially vulnerable 
in ALS. The alpha motor neurons can be subdivided into three different groups based on the 
contractile properties of their target muscle fibers: fast-twitch fatigable (FF), fast-twitch 
fatigue-resistant (FR), and slow-twitch fatigue-resistant (S).  
   
The S motor neurons are small, highly active, and have a low activation threshold. They 
innervate slow contracting muscle fibers which are dependent on oxidative metabolism. 
These fibers are very resistant to fatigue because of their rich content of mitochondria and 
their rich capillary blood supply. FF motor neurons are large, and have a higher activation 
threshold. They innervate fast contracting muscle fibers, which generate more force. These 
fibers rely on glycolysis for energy generation. The FR motor neurons are intermediate in size 
and innervate FR fibers, which are intermediate between the S and FF fibers.    
 
In mutant SOD1 mice, the FF motor neurons are the first to degenerate and are almost all 
lost by P50 75. Also in ALS patients the FF motor neurons are the ones affected earliest 76. 
The motor end plates, from which the degenerating FF axons have retracted, will 
subsequently be innervated by FR motor neuron axons. This leads to a switch in muscle fiber 
phenotype from FF to FR 77. Later in the disease process, the FR-motor neurons become 
involved, cannot maintain their neuromuscular junctions anymore and will retract their 
axons and degenerate. The S motor neurons will compensate for the degeneration of these 
axons by re-innervating motor end plates left by degenerating FF and FR motor neurons 75. 
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The axons of S motor neurons are involved in the terminal stages of the disease only. 
Moreover, electromyogram (EMG) patterns show similar cycles of denervation and re-
innervation in ALS patients as shown in the mutant SOD1 mouse 78.   
Interestingly, these physiologically different motor neurons also have different regeneration 
capacity. Mice treated with Botulinum toxin A, which blocks transmitter release, showed 
ultraterminal nerve sprouting 79. More sprouting synapses were detected in slow muscle 
fibers, while the FF motor neurons failed to sprout in fast muscle fibers 75.   
 
In summary, the large FF motor neurons are more vulnerable and degenerate first in ALS, 
followed by degeneration of the FR, intermediate in size, and only later by the small S motor 
neurons (Figure 1). The exact mechanism underlying this sequence is unknown. This 
vulnerability correlates with the intrinsic regeneration/sprouting capacity of these types of 
neurons. 
 
 
Figure 1 Vulnerability of motor neurons in ALS. The large FF motor neurons are more vulnerable to 
stress and have low sprouting capacity. These motor neurons degenerate first in ALS, followed by 
degeneration of the FR and S motor neurons.   
 
However, we have to keep in mind that this look at vulnerability of motor neurons is from 
the perspective of ALS. As previously mentioned, ALS forms a disease spectrum with FTD 
with mutations in certain genes giving rise to phenotypes throughout the spectrum 80. 
Furthermore, hexanucleotide expansions in C9Orf72 can give rise to several 
neurodegenerative diseases such as ALS, FTD and Huntington’s Disease (HD) 81. It is still 
unknown how mutations in one gene can give rise to different phenotypes as in FTD the 
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frontal and temporal lobe are affected and in ALS it are the motor neurons that degenerate. 
The concept of vulnerability awaits to be expanded in view of these considerations. 
 
 
1.2.4 ALS is a non-cell autonomous disease  
 
Expression of mutant SOD1 in the motor neurons solely is not sufficient to cause motor 
neuron degeneration 82-85. Indeed, a number of transgenic and transplantation experiments 
have demonstrated that other cells such as microglia, astrocytes and oligodendrocytes may 
be involved in the biology of ALS, at least in the mutant SOD1 mouse. Transgenic deletion or 
siRNA based downregulation of mutant SOD1 in motor neurons delayed disease onset, but 
did not alter disease progression 86-88. Deletion of mutant SOD1 from microglia slowed 
disease progression as did replacement of microglia expressing mutant SOD1 by 
nontransgenic microglia 86, 89-90. Deletion of mutant SOD1 from astrocytes slowed disease 
progression as well as transplantation of nontransgenic astrocyte precursor cells 91-92. 
Deletion of mutant SOD1 from oligodendrocytes dramatically delayed disease onset and 
prolonged survival 93. These experiments show that the presence of mutant SOD1 in motor 
neurons and oligodendrocytes may determine disease onset, while its presence microglia, 
astrocytes and oligodendrocytes accelerates disease progression. 
 
Astrocytes have pivotal functions in the healthy central nervous system, but also in 
pathological conditions 94. They can regulate synaptic transmission, maintain synaptic 
homeostasis and secrete components into the synapse such as lactate, glutamate and 
growth factors 94. Astrocytes are tightly linked through gap junctions and form a network 
enabling them to rapidly shuttle small molecules. Astrocytes also establish the blood brain 
barrier (BBB) by encircling endothelial cells with so called astrocytic end-feet 95. In response 
to Central Nervous System (CNS) injury and neurodegeneration, astrocytes become highly 
reactive in a process called astrogliosis 96. In this process, they upregulate glial fibrillary 
acidic protein (GFAP), nestin and connexin 43 (Cx43), which are used as markers for 
activation 97-98. Reactive astrocytes become hypertrophic which refers to the increased 
thickness of their processes 94, 99. Reactive astrocytes produce pro- and anti-inflammatory 
molecules, indicating that they have a dual effect, similar to what is seen for microglia (see 
below) 94. In ALS, familial and sporadic, reactive astrogliosis starts before disease onset and 
increases as the disease progresses. It is most pronounced in the ventral horn around the 
descending fibers of the corticospinal tract 100-101. Astrogliosis is also present in the motor 
cortex 101-102. Upon disease progression, there is a decrease in expression of glutamate 
transporter EAAT2, resulting in reduced glutamate clearance from the synaptic cleft 
rendering the motor neuron more vulnerable for glutamate-mediated excitotoxicity (see 
above) 54-58. ALS reactive astrocytes produce more nitric oxide compared to controls, which 
can contribute to the oxidative damage in ALS 103. Furthermore astrocytes containing mutant 
SOD1 secrete a toxic factor that selectively kills motor neurons but leaves dorsal root 
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ganglion neurons and interneurons unaffected, while they fail to secrete trophic factors that 
are secreted by control astrocytes 104-108.  
 
Microglia are the resident macrophages of the CNS and consequently act as the first and 
main form of immune defense in the CNS 109-110. They are constantly scanning their 
environment for damaging factors and change from a surveying state into an activated state 
when detecting one. Microglia can exert a deleterious function (M1 microglia) or a benign 
function (M2 microglia) depending on the microenvironment and the pathological insult 111-
112. M1 microglia secrete proinflammatory molecules and upregulate oxidant molecules to 
clear hazards and repair damage. M2 microglia release anti-inflammatory molecules and 
trophic factors contributing to repair and limiting inflammation. A shift from M1 to M2 
predominance is necessary for the shift from inflammation to repair 110, 112-113. In the spinal 
cord and brain of ALS patients strong microglial activation and proliferation is present 114-117. 
In the mutant SOD1 mouse, this microgliosis is already present before disease onset and 
escalates with disease progression 45, 118. Microglia isolated from mutant SOD1 mice at 
disease onset have an M2 phenotype whereas microglia isolated at end-stage have an M1 
phenotype 113.   
  
Oligodendrocytes are glial cells responsible for myelination in the CNS allowing rapid and 
efficient propagation of action potentials 119. Myelination is a key process in the developing 
brain and continues after birth up to 30 years of age 120. Remyelination also occurs during 
neuronal injury or degeneration 119. This process is not performed by existing mature 
oligodendrocytes, but involves generation of new oligodendrocytes from oligodendrocyte 
precursor cells (OPCs). OPCs can be found throughout grey and white matter and start 
proliferating in response to neuronal insult 121. In spinal cords of ALS mice and patients 
oligodendrocytes show morphological and functional changes starting before disease onset 
15, 122-124. Similarly to neurons, oligodendrocytes show mislocalisation of TDP43 which is a 
pathological hallmark of ALS 125. In spinal cords of ALS patients and mutant SOD1 mice, 
oligodendrocyte degeneration is observed 124. This degeneration of oligodendrocytes is 
compensated by enhanced proliferation and differentiation of OPCs. However these newly 
formed oligodendrocytes are dysfunctional as suggested by reduced expression of 
monocarboxylate transporter 1 (MCT1), a lactate transporter essential for the metabolic 
support of motor axons. This reduced MCT1 expression was also detected in ALS patients is 
also decreased in ALS mice and patients 15, 124. As a result the motor neurons loose an 
important source of trophic support 15, 93, 124.  
 
1.2.5 Mitochondrial dysfunction  
 
The large dimensions of the motor neurons implicit a high demand of energy and a high 
metabolic rate, which is supplied through a high level of mitochondrial activity 126. During 
mitochondrial oxidative phosphorylation reactive oxygen species (ROS) are formed, which 
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have important effects on cell signaling and homeostasis 127-128. ROS levels can increase 
dramatically upon stress which may result in an imbalance between production and 
decomposition of ROS. This oxidative stress can damage several cellular components such as 
proteins, lipids and DNA 128. In sporadic ALS patients, increased oxidative stress was detected 
compared to control samples 61. Furthermore, mitochondrial abnormalities such as 
vacuolization and swelling have been detected in mutant SOD1 mice, even in 
presymptomatic stages, as well as in ALS patients 129. It is uncertain whether these changes 
are primary or secondary in nature, but they may contribute to cell death in ALS as 
mitochondria contribute to calcium buffering (see below for excitotoxicity) and the 
regulation of apoptosis 59, 130. Mutant SOD1 mice show decreased levels of anti-apoptotic 
proteins and increased levels of pro-apoptotic proteins 131. These mice also showed an 
increased mitochondrial release of cytochrome c into the cytosol initiating the caspase 
pathway 132.  
 
1.2.6 Impaired axonal transport  
 
Motor neurons have very long axons that connect the cell body with the synapses. 
Impairment of axonal transport, both forward and reverse, has been shown to be affected 
even before disease onset 133-136. Both in ALS patients and mutant SOD1 mice abnormal 
accumulation of microfilaments in the cell body and in the axons has been observed 137-141. 
Abnormalities of the location of mitochondria throughout the motor neuron have been 
observed as well in ALS 126. Again, it is uncertain whether these changes are primary or 
secondary phenomena.   
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2 The ephrin axonal repellent system  
 
The family of Eph receptors is the largest of receptor tyrosine kinases and is named after the 
high EphA1 expression in an Erythropoietin-Producing human Hepatocellular carcinoma cell 
line 142. This family is subdivided in two classes (EphA and EphB) based on sequence 
similarity and ligand affinity 143. They interact with ephrin ligands that are also subdivided 
into two classes: ephrinA and ephrinB ligands. In the mammalian system there are nine EphA 
receptors (EphA1-EphA8, EphA10) that interact with five ephrinA ligands (efnA1-efnA5) and 
five EphB receptors (EphB1-EphB4, EphB6) that interact with three ephrinB ligands (efnB1-
efnB3). There is some interclass promiscuity as EphA4 also interacts with efnB ligands and 
EphB2 also interacts with efnA5 144-147. As both Eph receptors and ephrin ligands are 
membrane bound, cell-cell interaction is required for activation. Eph-ephrin interaction can 
induce both repulsion and attraction between cells as observed during cell migration and 
axon guidance 148-149.  
 
The ephrin system has major functions both in development and in adulthood. During 
embryonic development, the ephrin system plays a role in axon guidance, formation of 
tissue boundaries, cell migration, segmentation and angiogenesis 150-153. In adulthood it plays 
an important role in long-term potentiation, bone mineral metabolism, T-cell and stem cell 
differentiation 154-157. Eph-ephrin signaling has also been implicated in the pathogenesis of 
several diseases 158-160. Both Eph receptors and ephrin ligands are expressed in cancer cells 
and tumor vasculature. They have been shown to affect growth, migration, invasiveness, 
angiogenesis and metastasis of different types of tumors. Furthermore, the ephrin system is 
also involved in repair after nervous system injury, neurodegenerative disorders, diabetes, 
viral infections and bone remodeling diseases 159.  
 
 
2.1 Eph receptor structure  
 
The Eph receptor extracellular domain consists of an N-terminal ligand-binding domain 
(LBD), a cysteine-rich domain (CRD) with a Sushi domain and an Epidermal Growth Factor 
(EGF)-like domain and two fibronectin (FN) type III repeats (Figure 2) 161. The intracellular 
domain consists of a juxtamembrane domain with two conserved tyrosine residues, a kinase 
domain, a sterile α-motif (SAM) and a PDZ-binding motif (post synaptic density protein 95 
(PSD-95) Drosophila discs-large imaginal disc protein (DlgA) ZO-1 tight junction).   
 
The LBD determines the affinity for the ephrin ligands. It contains a hydrophobic channel and 
a polar docking site on the lower site of the LBD, of which the latter is only of importance for 
interaction with ephrinB ligands 144, 146.  
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Figure 2 Schematic representation of the Eph receptor and the ephrin ligands. The Eph extracellular 
domain contains a ligand-binding domain (LBD), a cystein-rich domain (CRD) with a Sushi domain and 
an Epidermal Growth Factor (EGF)-like domain and two fibronectin type III repeats. The Eph 
intracellular domain consists of a juxtamembrane region, a kinase domain, a Sterile alpha (SAM) 
domain and a PDZ-binding motif. EphrinB ligands contain cytoplasmic domain with a PDZ-binding 
domain at the C-terminus. EphrinA ligands are attached to the cell-membrane with a 
Glycosylphosphatidyl Inositol (GPI)-anchor. Figure based on several articles 161-163. 
 
In the inactive state, the juxtamembrane region tightly associates with the kinase domain 
(Figure 3) 164. Upon ephrin binding, Eph receptors are activated, which is characterized by 
the phosphorylation of two tyrosine residues in the juxtamembrane region and one tyrosine 
residue in the kinase domain (Figure 3) 165-166. Phosphorylation of the tyrosine residue in the 
kinase domain induces repositioning of this segment, unblocking the kinase active site. It is 
still unclear how ephrin binding induces Eph receptor autophosphorylation. One possibility is 
that ephrin binding increases the local concentration of receptors thereby promoting 
transphosphorylation. Another possibility is that Eph receptor clustering physically 
destabilizes the juxtamembrane region initiating receptor activation (Figure 3, further 
discussed in 2.3 Eph/ephrin clustering) 167.  
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Figure 3 Schematic representation of Eph/ephrin clustering. In the inactive state the 
juxtamembrane region associates tightly with the kinase domain. Eph/ephrin clustering starts with 
the recognition and binding of Eph receptors and ligands on opposing cell surfaces. Heterodimers are 
formed, which can tetramerize into heterotetramers, thereby forming a ring structure in which each 
receptor interacts with two ligands and each ligand interacts with two receptors. Receptor activation 
includes the phosphorylation of tyrosine residues in the juxtamembrane region and in the kinase 
domain. These clustering interfaces allow binding of other heterotetramers resulting in an array of 
well-ordered Eph receptors. This clustering also results in lateral recruitment of non-ligand-bound 
Eph receptors. Figure based on several articles 149, 161-162, 168-169. 
 
Several of the extracellular and intracellular domains are involved in the formation of 
Eph/ephrin clusters, including the CRD, FNIII repeats, SAM 170. The FNIII repeats are also 
involved in cis-interaction with ephrin ligands 163, 171-172. The SAM domain is not essential for 
Eph clustering, but may stabilize the array of clustered Eph receptors 161, 173-174. 
 
After clustering, several tyrosine residues are phosphorylated forming binding sites for 
intracellular adaptors 175. Phosphorylation of the tyrosine residues in the juxtamembrane 
region form binding sites for cytoplasmic targets with Src Homology 2 (SH2) or 
Phosphotyrosine binding (PTB) domains. Oligomerization and phosphorylation of the SAM 
domain creates interaction sites for downstream signaling molecules such as protein 
tyrosine phosphatases (PTP) 176-177.   
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2.2 Ephrin ligand structure  
 
All ephrin ligands contain a conserved receptor-binding domain (RBD). The RBD contains a 
hydrophobic loop that is inserted into the hydrophobic core of the LBD upon receptor 
binding. Ephrin ligands are subdivided in two classes based on the way they are attached to 
the cell membrane (Figure 2). EphrinA ligands are attached to the cell membrane via a 
Glycosylphosphatidyl Inositol (GPI) anchor. However, as they lack a cytoplasmic domain, 
they depend on the association with co-receptors (p75NTR (p75 neurotrophin receptor), Ret 
(rearranged during transfection) and TrkB (Tropomyosin receptor kinase B)) for further 
signaling 178-180. EphrinB ligands contain a transmembrane domain followed by a conserved 
cytoplasmic region and a C-terminal PDZ-binding motif 181. This cytoplasmic region contains 
tyrosine residues that become phosphorylated upon receptor binding 182-183.  
 
 
2.3 Eph/ephrin clustering  
 
To obtain full biological activity Eph receptors need to be clustered, through a seeding 
mechanism 168. This mechanism involves two interaction interfaces: the heterodimerization 
interface between receptor and ligand, and the clustering interface between two adjacent 
Eph receptors. Eph/ephrin clustering starts with the recognition and binding of Eph 
receptors and ligands on opposing cell surfaces (Figure 3) 161. Heterodimers are formed, 
which can tetramerize into heterotetramers, thereby forming a ring structure in which each 
receptor interacts with two ligands and each ligand interacts with two receptors (Figure 3) 
184. This heterotetramerization has been observed both for EphA/efnA and EphB/efnB 
clustering 184-185. The Eph/ephrin heterotetramers assemble into hetero-oligomeric clusters 
via direct Eph/Eph interactions. Most likely these clustering interfaces allow them to bind to 
other heterotetramers resulting in an array of well-ordered Eph receptors. This clustering 
also results in lateral recruitment of non-ligand-bound Eph receptors 186. The clustering 
interfaces involve LBD-LBD interactions through salt bridges and hydrogen bonds, and CRD-
CRD interactions through van der Waals interactions 170, 185, 187. Interaction between 
fibronectin repeats has also been suggested, but this has not been confirmed 163, 185.   
 
Only ligands that are clustered (both membrane-bound ligands and artificially clustered 
ligands) can trigger signaling, while non-clustered or soluble ligands act as antagonists 175, 188-
191. Moreover, clustering of ephrin ligands increases the local Eph receptor concentration, 
thereby stimulating downstream signaling 168.  
 
 
  
 
 
27 
 
In normal conditions, Eph receptors and ephrin ligands are present at the cell surface in 
distinct membrane regions, the cholesterol-rich lipid rafts 192. These rafts enable trans-
signaling between Eph receptors and ephrin ligands on opposing cells, and block cis-
interactions between Eph receptors and ephrin ligands on the same cell 192-193. Cis-
interaction makes Eph receptors less responsive to ephrin ligands in trans abolishing the 
induction of tyrosine phosphorylation (Figure 4) 149.   
 
 
Figure 4 Cis-interaction between ephrin ligands and Eph receptors. This cis-interaction abolishes the 
induction of tyrosine phosphorylation and makes Eph receptors less responsive to ephrin ligands in 
trans. Adapted from Pitulescu et al., 2010 149. 
 
2.4 Signaling 
 
Interaction between Eph receptors and ephrin ligands can result in bidirectional signaling: 
forward signaling in the Eph-bearing cell and reverse signaling in the ephrin-bearing cell 
(Figure 5) 159. The Eph-ephrin signal is complex due to a large number of possible Eph-ephrin 
interactions, co-expression of different Eph receptors, cis-interaction influencing the signal 
and cross-talk with other signaling pathways 175. This complexity makes it difficult to clearly 
define the signaling pathways underlying many Eph functions 175. Signaling from the same 
Eph-ephrin pair can result in opposing responses, such as adhesion and retraction, 
depending on cell type, tissue and organ context. In general, Eph receptor phosphorylation 
results in cell-cell segregation while the same Eph receptor can stimulate cell-cell adhesion 
via kinase-independent signaling pathways 149, 194. Many of the functions of Eph receptors 
involve signaling in both ways regulating cytoskeleton dynamics and morphology. One of the 
most common cellular responses to Eph receptor activation is actin stress fiber 
depolymerisation leading to cytoskeletal collapse, inducing cell-cell segregation 194.   
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Figure 5 Bidirectional signaling. Interaction between Eph receptors and ephrin ligands can result in 
signaling in two directions: signaling in the Eph-bearing cell (forward signaling) and signaling in the 
ephrin-bearing cell (reverse signaling). Adapted from Pitulescu et al., 2010 149. 
 
 
 
2.5 Regulation of Eph/ephrin signaling  
 
The Eph/ephrin interaction and subsequent signaling is regulated in different ways and at 
different levels. At the RNA level there is transcriptional and post-transcriptional regulation 
195. Eph/ephrin signaling is also influenced by different interaction partners such as ligand-
interaction in cis, protein tyrosine phosphatases (PTPs), γ-secretases and matrix 
metalloproteinases (MMP) such as A Disintegrin and Metalloproteinase (ADAM). Ligand 
interactions in cis make Eph receptors less responsive to ephrin ligands in trans 149, 172. PTPs 
block Eph receptor phosphorylation and counteract Eph receptor endocytosis 196-197.  ADAM 
interaction with Eph receptors is promoted by ephrin-induced clustering (Figure 6A). ADAM 
cleaves ephrinA ligands, thereby disrupting the Eph/ephrin interaction, resulting in cell de-
adhesion. EphrinB ligands are cleaved both by MMPs and y-secretases, producing an 
intracellular domain (ICD) which activates downstream signaling 198. This process of cleavage 
has been reported for the EphA4 and EphB2 receptor 199-201. Another mechanism to 
terminate Eph/ephrin interaction is trans-endocytosis involving the uptake of full-length 
transmembrane EphB-ephrinB signaling complexes in the cell, enabling cell de-adhesion 
(Figure 6B) 149. Whether the Eph/ephrin complex is taken up by the cell with the Eph 
receptor or the cell with the ephrin ligand, is determined by the Eph/ephrin signaling as this 
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process requires a functional Eph kinase. However, the exact mechanism is not completely 
understood 202.   
 
 
Figure 6 Regulation of Eph/ephrin signaling. (A) Upon clustering ADAM cleaves ephrinA ligands, 
thereby disrupting the Eph/ephrin interaction and inducing cell de-adhesion. (B) Trans-endocytosis 
involving the uptake of full-length transmembrane EphB-ephrinB signaling complexes in the cell, 
enabling cell de-adhesion. Adapted from Pitulescu et al., 2010 149.  
 
 
2.6 Epha4 
 
In the CNS, Epha4 is highly expressed in cell bodies, dendritic spines and axons of neurons in 
various brain regions 203-204. Neuronal Epha4 expression regulates dendritic spine 
morphology, which plays an important role in synaptic plasticity including long-term 
potentiation (LTP) and long-term depression (LTD) 201, 205-206, while synaptic activity itself is 
able to increase Epha4 phosphorylation 207. Furthermore, Epha4 has been shown to be 
involved in several neurological disorders including acute injuries, neuroinflammation and 
neurodegenerative diseases 175.   
 
 
2.6.1 CNS trauma  
 
Total EphA4 expression has been found to be upregulated in reactive astrocytes in brains of 
traumatic brain injury (TBI) patients who deceased more than one day after the injury 208, 
while phosphorylated EphA4 levels were significantly increased both in the ipsi- and 
contralateral hemisphere of individuals who died more than 8 hours after TBI 208. In mouse 
models, this upregulation was only found in the cortex ipsilateral to the injury, but not in the 
hippocampus. Disappointingly, transgenic reduction of Epha4 levels in the hippocampus and 
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cortex did not result in improved outcome 209.    
The results obtained in studies on spinal cord injury (SCI) have been somewhat inconsistent.  
Some 210-212 but not all 213-214 studies have found Epha4 to be upregulated in reactive 
astrocytes at the lesion site 210-211 and in the proximal axonal stumps 212. Epha4-/- mice 
showed increased axonal regeneration, which was shown by forward labeling of axons 
crossing the lesion site in Epha4-/- mice 210. Furthermore, in rats treated with an EphA4 
inhibitor, corticospinal tract axons sprouting was enhanced 213. Both genetic knockdown as 
well as pharmacological blocking of Epha4 improved functional recovery including walking, 
climbing and grasping in mice after SCI 210, 213. Disappointingly, this enhanced functional 
recovery was not seen in a rat model for SCI in which Epha4 expression was reduced using 
Epha4 antisense-oligodeoxyncleotides 215.   
 
2.6.2 Stroke 
 
Epha4 was found to be highly upregulated in several experimental stroke models. In a focal 
cerebral ischemia rat model, Epha4 was highly upregulated in the glial scar 7 and 14 days 
after ischemia 214. In a forebrain ischemia-reperfusion rat model, Epha4 was also found to be 
upregulated in the CA1 region 216. Furthermore, higher expression of Epha4 was also shown 
in sprouting neurons after stroke in aged mice compared to sprouting neurons in younger 
mice, which may contribute to the reduced functional recovery in aged mice 217. Inhibiting 
Epha4 by Epha4-Fc delivery in mice seven days post-stroke enhanced sprouting within the 
motor cortex 218.   
 
Downregulation as well as inhibition of Epha4 enhanced recovery after stroke in two 
different experimental stroke models 216, 219. In a mouse model of photothrombotic stroke, 
enhanced motor recovery was observed in mice with reduced expression of Epha4 219. 
Blocking Epha4 by Epha4-Fc delivery 30 minutes after ischemia-reperfusion in rats, lead to 
attenuated apoptotic neuronal death, suggesting a neuroprotective effect of Epha4 
inhibition 216.  
 
  
2.6.3 Multiple Sclerosis (MS)  
 
In active MS lesions in the human brain, EphA4 was found to be upregulated in inflammatory 
cells, macrophages, reactive astrocytes and axons 220. In mice with experimental 
autoimmune encephalomyelitis (EAE), a model for MS, Epha4 was expressed on reactive 
astrocytes surrounding lesions 221. In Epha4-/- mice with EAE, disease onset was delayed and 
its course less severe. Pharmacological blocking of Epha4 using soluble Epha4-Fc also 
delayed disease onset and slowed disease evolution. Genetic and pharmacological inhibition 
of Epha4 did not affect histopathological characteristics of the lesions including the numbers 
of infiltrating T-cells and macrophages, the number and size of the lesions and the extent of 
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astrocytosis, although axonal abnormalities were attenuated in Epha4-/- mice with EAE 221.
  
  
2.6.4 ALS 
 
The clinical presentation of ALS varies greatly between ALS patients. Even within one family 
carrying the same mutation, disease onset and disease progression can be very 
heterogeneous 2, 28. This suggests that ALS is a multifactorial disease influenced by modifying 
genes and environmental factors.  In previous experiments in our laboratory, a zebrafish 
model of ALS was used to screen for modifying genes that could rescue the axonal 
phenotype. This axonal phenotype, shorter and more aberrantly branched motor axons, is 
caused by overexpression of mutant SOD1 in zebrafish embryos 13. A morpholino-based 
knockdown of receptor tyrosine kinase 2 (rtk2), the zebrafish orthologue of human EphA4, 
completely rescued the axonal phenotype 35. This result was confirmed in the SOD1G93A ALS 
mouse model where deletion of only one Epha4 allele resulted in a longer survival compared 
to controls. In blood samples of ALS patients an inverse correlation was identified between 
EphA4 expression and disease onset suggesting lower levels of EphA4 to be associated with a 
less severe phenotypic expression of the disease. Sequencing of EphA4 in humans with ALS 
identified two previously unknown mutations which are associated with unusual long 
survival.  
  
As genetic interference had a beneficial effect in the ALS fish and mouse model, it was also 
tested whether pharmacological inhibition could result in a beneficial effect. The small 
compound, a 2-hydroxy-4(2, 5-dimethylpyrrol-1-yl) benzoic acid derivative (C1), completely 
rescued the axonal phenotype in the zebrafish model of ALS. Intracerebroventricular 
delivery of the KYL-peptide delayed onset and increased survival in the SOD1G93A rat model. 
This dodecapeptide is a specific EphA4 antagonist which has been extensively studied in vitro 
and in vivo with beneficial effects in spinal cord injury 213, 222. The properties of C1 will be 
further discussed in Chapter 4.   
 
 
2.6.5 Alzheimer’s Disease (AD)  
 
In the hippocampus of AD patients in the initial stage of the disease, EphA4 expression was 
found to be decreased and in their frontal lobe, the expression of the EphA4 intracellular 
domain (EICD) was reduced 223-224. This fragment is obtained after cleavage of EphA4 by γ-
secretase and enhances the formation of dendritic spines 201. Furthermore, increased 
abundance of EphA4 has been found in neuritice plaques, although this study did not find a 
difference in EphA4 expression 225.   
In the hippocampus of two AD mouse models 223, but not in two other ones 226-227, Epha4 
expression was reduced, even before the occurrence of behavioral changes. However, in the 
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AD mouse models where no difference in Epha4 expression was found, an increase in Epha4 
activity could be detected 226-227. This enhanced Epha4 activation was also seen in 
hippocampal slices, cultured neurons and synaptoneurosomes exposed to amyloid beta (Aβ) 
oligomers 227-228.  
Experimental AD mice showed decreased long-term potentiation (LTP) that was rescued 
when Epha4 was genetically or pharmacologically downregulated 227. Pharmacological 
blocking of the Epha4 receptor also rescued LTP in an in vitro model for Aβ toxicity 228. 
 
 
2.6.6 Parkinson’s Disease (PD) and Huntington’s Disease (HD)  
 
In a study searching for biomarkers in cerebrospinal fluid (CSF) of PD patients, a peptide 
derived from EphA4 was found to be abundantly present 229. In HD brains, decreased EphA4 
mRNA levels have been found, and decreased EphA4 protein levels in the CSF of HD patients 
have been reported 230. No functional studies in models for these disorders have been 
performed.  
 
2.6.7 Conclusion 
 
In spite of some inconsistencies in terms of Epha4 expression, an increase in Epha4 activity 
as measured by Epha4 phosphorylation was observed in all disorders. In agreement with 
this, and again in spite of inconsistencies of results obtained using different strategies, 
blocking Epha4 positively affected the functional outcome in all neurological disorders 
tested, suggesting that Epha4 activation negatively affects the pathogenesis of these 
disorders.  
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Aims 
 
The variability of the phenotypic expression of ALS is unexplained, but it is thought to be 
genetic and/or environmental in nature. We previously identified the Epha4 receptor to be 
contributing to this variability. Knockdown of Epha4 in the zebrafish model of ALS resulted in 
a rescue of the axonal phenotype. Epha4 deletion and inhibition of the receptor resulted in 
increased survival in the ALS mouse and rat model respectively. Furthermore EphA4 
expression in blood of sporadic ALS patients inversely correlated with survival indicating that 
patients with higher EphA4 expression have shorter survival. With the present work, we aim 
to gain more insight in the pathogenesis of ALS by studying the mechanism of action of 
Epha4 (I) and to test the therapeutic potential of modifying Epha4 in ALS (II).   
    
The aim of part one is to investigate the mechanism of action of the hazardous effect of 
Epha4 on ALS. The ephrin system is a very complex system due to a large number of possible 
Eph-ephrin interactions, bidirectional signaling, co-expression of different Eph receptors, cis-
interaction influencing the signal and cross-talk with other signaling pathways. To unravel 
the mechanism of action of the hazardous effect of Epha4 on ALS, we will focus on the effect 
of the Epha4 receptor on motor neuron degeneration and on the role of its interaction 
partners.  
 
The aim of part two is to explore the therapeutic potential of EphA4 antagonists in the 
pathogenesis of ALS. We will test the potential of existing EphA4 antagonists. In addition, as 
most existing EphA4 inhibitors lack specificity and only block EphA4 activation at higher 
concentration, we will use Nanobody technology to generate a new, selective EphA4 
inhibitor.  
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Part I: Exploring the mechanism of the beneficial 
effect of EphA4 inhibition in ALS 
 
Introduction 
 
We previously showed that EphA4 is a modifier of ALS both in animal models and in patients 
35. In a mouse model of ALS, the SOD1G93A mouse, genetically reducing the levels of Epha4 to 
half of the normal levels resulted in increased motor performance and survival. 
Histopathological analysis showed that more ventral horn motor neurons were preserved in 
mice with reduced Epha4 levels, Epha4+/-; SOD1G93A mice, compared to their littermate 
controls. Furthermore, Epha4+/-; SOD1G93A mice had a higher percentage of fully innervated 
neuromuscular junctions. These data indicate that 50% reduction of Epha4 expression slows 
motor neuron degeneration in the SOD1G93A ALS mouse model. Interestingly, these findings 
could be translated to human ALS, as an inverse correlation between EphA4 expression in 
blood samples and disease onset was identified in sporadic ALS patients.   
 
We next studied the mechanism through which Epha4 exerted its role as a modifier of motor 
neuron degeneration. We previously studied the possible effect of decreased Epha4 
expression on gliosis and excitotoxicity. Indeed, in an animal model for spinal cord injury a 
reduction of Epha4 was shown to be associated with a decrease in gliosis, which is of interest 
since astrocytes are important contributors to motor neuron degeneration in ALS 210. 
However, in ALS mice with reduced Epha4 no reduction in gliosis was observed 35. 
Furthermore, the expression of the glial glutamate transporter (GLT1) was demonstrated to 
be upregulated in the hippocampus of mice with lower levels of Epha4 205. Excitotoxicity is a 
generally accepted mechanism in ALS, and therefore, we hypothesized that the beneficial 
effect of reduced Epha4 expression may be explained by an upregulation of GLT1 in the 
spinal cord of ALS mice. However, although an upregulation of GLT1 was confirmed in the 
hippocampus, no change of GLT1 expression was found in the spinal cord of Epha4+/-; 
SOD1G93A mice 35.   
In part I of this thesis, we further studied the mechanism through which Epha4 modifies ALS. 
We explored the contribution of Epha4 to the vulnerability of motor neurons and their 
sprouting potential following injury (Chapter 1). Furthermore, we studied whether the effect 
of Epha4 on motor neuron degeneration is mediated through forward or reverse signaling 
(Chapter 2). Finally, we investigated the possible involvement of one particular Epha4 ligand, 
ephrinb2, in the pathogenesis of ALS (Chapter 3). 
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Chapter 1. Epha4 as a vulnerability factor in motor neurons   
 
Published in: Van Hoecke A et al., Nature Medicine, 2012  
Experiments in collaboration with Annelies Van Hoecke 
1.1 Introduction 
 
In previous work studying the spinal cord of mice overexpressing human wild type SOD1 
(SOD1WT) or mutant SOD1 (SOD1G93A), we found Epha4 to be mainly or even exclusively 
present in spinal cord motor neurons, as it was below detection threshold in other cell types, 
such as astrocytes or microglia 35.  
In ALS, motor neurons are selectively affected. Some mechanisms that may at least partially 
explain the vulnerability of motor neurons have been discussed above. Interestingly, not all 
motor neurons are equally vulnerable. There are subpopulations of motor neurons such as 
the oculomotor neurons and neurons in Onuf’s nucleus that are more resistant to 
neurodegeneration. Furthermore, there are motor neurons with different physiological 
characteristics that are also differentially vulnerable in ALS.  
The aim of the present study was to further study the role of Epha4 in motor neurons during 
disease development and progression in ALS and to elucidate whether Epha4 contributes to 
the vulnerability of motor neurons.  
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1.2 Results  
1.2.1 Vulnerable motor neurons in ALS have higher expression of Epha4  
  
Epha4 protein expression in lysates of lumbar spinal cord decreases during disease 
progression in mutant SOD1 mice 35. We first studied whether this decrease merely reflects 
the decrease of the number of motor neurons known to occur during ALS. To this end, we 
quantified Epha4 expression in motor neurons of the anterior horn of the spinal cord. Motor 
neurons from the spinal cord of SOD1G93A mice were isolated at different time points during 
the disease using Laser Capture Microdissection (LCM) followed by quantification of Epha4 
mRNA expression using quantitative Polymerase Chain Reaction (qPCR) (Figure 1.1A). 
Surprisingly, Epha4 levels in motor neurons were reduced in late-symptomatic mice, 
compared to pre-symptomatic mice. This suggests that expression within the motor neuron 
is decreasing when the disease progresses or that motor neurons with higher levels of Epha4 
are the most vulnerable as they die off first, while motor neurons with low Epha4 levels are 
less vulnerable, as they appear to survive until the late stages of the disease (Figure 1.1B).  
 
Figure 1.1 Motor neurons in late-symptomatic mice have lower levels of Epha4. (A) Image of ventral 
horn of lumbar spinal cord before (left) and after (right) LCM. (B) Epha4 mRNA expression in 
microdissected motor neurons of presymptomatic (Pre-sym) and late-symptomatic (Late-symp) 
SOD1G93A mice and age-matched SOD1WT mice (ANOVA p = 0.0033, n = 3). Polr2a was used as internal 
control, and levels were subsequently normalized to the 60-d value obtained in SOD1WT mice. 
Adapted from Van Hoecke et al., 2012.  
 
Differential vulnerability of motor neurons in ALS has been related to size and physiological 
subtype. Large, FF motor neurons are more vulnerable231. We therefore studied the 
expression of Epha4 in relation to size of the motor neuron. As shown in figure 1.2A., large 
motor neurons appear to be more susceptible to ALS, as has been described previously231. 
Interestingly, Epha4 expression was significantly higher in microdissected large motor 
neurons (> 600 µm²) compared to that in smaller motor neurons (250 - 400 µm²) (Figure 
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1.2B). In agreement with this, we found that the protective effect of a reduction of Epha4 in 
SOD1G93A mice was most pronounced in the large motor neurons (Figure 1.2C). Thus, 
expression levels of Epha4 correlate with vulnerability of neurons to ALS.  
 
Figure 1.2 Vulnerable motor neurons in ALS have higher expression of Epha4. (A) Relative number 
of small (250–400 μm2) and large (>600 μm2) motor neurons in the ventral horn of spinal cord of late-
symptomatic SOD1G93A mice (n = 9) and age-matched SOD1WT controls (n = 6; two-way 
ANOVA, pgenotype × motor neuron size = 0.018, t-test small motor neurons p = 8.1 × 10
−4, t-test large motor 
neurons p = 2.80 × 10−5). (B) Epha4 expression in small and large laser-captured microdissected 
motor neurons of nontransgenic mice (n = 3, t-test p = 0.044). Polr2a was used as internal control. (C) 
Relative number of small and large motor neurons in the spinal cord of late-symptomatic Epha4+/−; 
SOD1G93A mice (n = 9) compared to age-matched Epha4+/+; SOD1G93A littermates (n = 9; two-way 
ANOVA pgenotype × motor neuron size = 0.031, t-test small motor neurons p = 0.018, t-test large motor 
neurons P = 0.011). Adapted from Van Hoecke et al., 2012. 
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1.2.2 Epha4 is a determinant of the re-innervating capacity of motor neurons 
 
We then wondered whether Epha4 is just a marker of vulnerable neurons, or whether it 
plays a mechanistic role. Large motor neurons have limited regenerating capacity as 
evaluated by sprouting and reduced re-innervation capacity. Therefore, vulnerability and 
regeneration capacity are thought to be interrelated 75.  We therefore studied the role of 
Epha4 in re-innervation capacity of the motor neuron by investigating its effect on 
neuromuscular re-innervation following axotomy of the sciatic nerve (Figure 1.3A). As shown 
in figure 1.3B, the re-innervation capacity in Epha4 knockout mice was significantly and 
dose-dependently improved compared to wild type mice, suggesting that Epha4 reduces the 
re-innervating capacity of spinal motor neurons (Figure 1.3B).   
 
 
Figure 1.3 Epha4 is a determinant of the re-innervating capacity of motor neurons . (A) Schematic 
representation of sciatic nerve axotomy. (B) Re-innervation of gastrocnemius neuromuscular 
junctions after sciatic nerve axotomy in Epha4+/+ (n = 10), Epha4+/− (n = 8, OR 2.15 ± [1.76–2.63]) 
and Epha4−/− mice (n = 5, OR 4.98 ± [3.93–6.31]).  ***p< 0.001. Adapted from Van Hoecke et al., 
2012. OR, Odds ratio 
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1.3 Discussion 
 
Previous work in our laboratory has shown that Epha4 is a modifier of ALS. However, the 
mechanisms by which Epha4 reduction/inhibition attenuate motor neuron degeneration 
remain unknown. In SOD1G93A mouse with 50% reduction of Epha4 expression, astrogliosis 
and GLT1 expression were not altered. In this chapter we showed that motor neurons with 
lower levels of Epha4 are less vulnerable as they survived until the late stages of the disease. 
Large motor neurons that are more vulnerable have higher Epha4 expression compared to 
smaller motor neurons. In agreement with this, the protective effect of reduced Epha4 
expression in the SOD1G93A mouse was most pronounced in the large motor neurons. 
Furthermore, reduced Epha4 expression improved the re-innervating capacity of spinal 
motor neuron axons in a model of sciatic nerve axotomy. Together these results suggest that 
Epha4 contributes to the differential vulnerability of motor neurons in ALS and that high 
Epha4 expression reduces the re-innervating capacity of large motor neurons, possibly 
making them vulnerable for degeneration and thereby attenuating ALS disease progression 
(Figure 1).  
  
Mutant SOD1 mice resemble to a remarkable degree the precise pattern in selective motor 
neuron degeneration both in terms of regional vulnerability and motor neuron subtype seen 
in patients with sporadic ALS. Similar to what is seen in mutant SOD1 mice, the large motor 
neurons are the ones affected earliest in ALS patients 78. Moreover, EMG patterns of single 
motor units in a distal muscle in ALS patients show similar patterns of denervation and re-
innervation 76. This de- and re-innervation results in fiber type grouping, characteristic for 
what is seen in ALS patients 232. It is thought that sprouting from surviving motor neurons 
can compensate for the motor neuron degeneration in early stages of the disease. Even 
though a similar pattern in selective motor neuron degeneration is observed in ALS patients, 
we don’t know whether EphA4 also contributes to the vulnerability in motor neurons in ALS 
patients. Further experiments, including determining EphA4 expression within human motor 
neurons, might help to elucidate whether EphA4 contributes to the vulnerability of motor 
neurons in ALS patients.  
Several other factors have been identified that contribute to the differential vulnerability of 
motor neurons in ALS. MMP9 has been identified to be selectively expressed in the 
vulnerable motor neurons, more specifically in the fast motor neurons 74. These fast motor 
neurons (FF) are the ones affected earliest both in mutant SOD1 mice as in ALS patients 75-77. 
The degeneration of these FF motor neurons is followed by degeneration of the FR motor 
neurons and only later by the S motor neurons. There is compensatory re-innervation which 
differs between the different motor neuron sybtypes. The motor end plates, from which the 
degenerating FF axons have retracted, will subsequently be innervated by FR motor neuron 
axons. Later in the disease process, the FR-motor neurons become involved, cannot maintain 
their neuromuscular junctions anymore and will retract their axons and degenerate. The S 
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motor neurons will compensate for the degeneration of these axons by re-innervating motor 
end plates left by degenerating FF and FR motor neurons 75. The axons of S motor neurons 
are involved in the terminal stages of the disease only. This regeneration/sprouting capacity 
of different motor neurons subtypes correlates with its vulnerability and is important in the 
pathogenesis of ALS. Experimental increase of motor unit activity in the hind limbs of mutant 
SOD1 mice saved the motor units that are normally lost during early stages of the disease 
suggesting that the vulnerable motor units are saved by increasing their neuromuscular 
activity thereby converting them to more resistant motor units 233. Furthermore, FF and FR 
motor neurons in mutant SOD1 mice lacking MMP9 both adopt an axonal dieback 
phenotype comparable to that of S motor neurons as their rate of muscle denervation was 
similar to that of S motor neurons with normal MMP9 levels 74.  The exact mechanism 
underlying this sequential degeneration of the different motor neuron subtypes is unknown. 
However, it has been shown that UPR activation is initiated selectively in the vulnerable 
motor neurons and activated in resistant motor neurons late in disease, shortly before they 
start to degenerate 45. In mutant SOD1 mice with a deletion of MMP9 the UPR was initiated 
at later stages, suggesting MMP9 enhances the activation of the UPR thereby inducing 
axonal degeneration 74.   
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Chapter 2. Exploring the Epha4 signaling direction  
 
Experiments in collaboration with Laura Rué 
2.1 Introduction 
 
Interaction between Eph receptors and ephrin ligands can result in signaling in two 
directions: signaling in the Eph-bearing cell (forward signaling) and signaling in the ephrin-
bearing cell (reverse signaling) (Figure 5). Reduction of Epha4 expression results in decreased 
Epha4 signaling in both directions. It is unknown which signaling direction is involved in the 
modifying effect of Epha4 (Figure 2.1). To study the contribution of forward and reverse 
signaling on the beneficial effect observed upon Epha4 reduction, we obtained a transgenic 
mouse in which the Epha4 receptor is modified to lack forward signaling, but in which 
reversed signaling is unaffected 206. In this Epha4eGFP/eGFP mouse the cytoplasmic domain has 
been replaced by an enhanced Green Fluorescent Protein (eGFP), removing all intracellular 
binding sites. Previous studies already used this mouse model to distinguish between 
forward and reverse signaling. Both homozygous Epha4eGFP/eGFP and Epha4-/- mice show 
aberrant organization of thalamocortical projections 234-235. However, in contrast to Epha4-/- 
mice, long-term potentiation (LTP) is not affected in Epha4eGFP/eGFP mouse 206. These date 
indicate that Epha4 forward signaling is required for corticospinal tract formation, while 
Epha4 reverse signaling is involved in LTP. These aberrations in the formations of the 
corticospinal tract result in a rabbit-like hopping gate in both the Epha4-/- and Epha4eGFP/eGFP 
mice 234, 236.  Since the motor performance is difficult to assess in these homozygous Epha4-/- 
and Epha4eGFP/eGFP mice due to the hopping gate, survival and motor performance were 
assessed using Epha4+/-; SOD1G93A and Epha4eGFP/+ mice 234.   
 
We first molecularly characterized the Epha4eGFP/+ mice and then investigated the effect of 
replacing Epha4 by Epha4eGFP on the course of ALS. We hypothesized that if a similar 
protective effect on ALS is observed in the Epha4eGFP/+; SOD1G93A mice as in the EphA4+/-; 
SOD1G93A, the beneficial effect is mediated by a decrease of forward signaling. However, if 
no effect is observed in the Epha4eGFP/+; SOD1G93A mice, the beneficial effect observed in the 
Epha4+/-; SOD1G93A mice is caused by a decrease in reverse signaling.   
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Figure 2.1 Schematic representation of the Epha4+/- mouse and the Epha4eGFP/+ mouse. In the 
Epha4+/- mouse, Epha4 is deleted abolishing both the forward and the reverse signaling. In the 
Epha4eGFP/+ mouse, one Epha4 allele is replaced with an Epha4eGFP isoform abolishing only the 
forward signaling. 
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2.2 Results 
 
2.2.1 Epha4 expression and phosphorylation 
 
We determined the expression of the Epha4eGFP isoform and wild type Epha4 protein in 
lysates of spinal cord, hippocampus and cortex using an N-terminal Epha4 antibody since this 
detects both wild type Epha4 as well as the Epha4eGFP isoform (Figure 2.2A,B). 
Quantification of their expression levels in the heterozygous Epha4eGFP/+ mice showed higher 
expression of the Epha4eGFP isoform compared to wild type Epha4 (Figure 2.2C,D).   
 
 
Figure 2.2 Expression levels of wild type Epha4 and Epha4eGFP in CNS of adult mice. (A) A 
monoclonal antibody against the extracellular part of Epha4 recognised wild type Epha4 and 
Epha4eGFP in adult spinal cord (SC), hippocampus (Hipp) and cortex (Cx). (B) An antibody against GFP 
identified the lower band as Epha4eGFP. (C,D) Expression levels of wild type Epha4 (n = 4, 100%) and 
Epha4eGFP (n = 4, 143%) in the spinal cord of Epha4eGFP/+ mice (p = 0.0122). GAPDH (37 kDa) was 
used as a loading control. *p<0.05. Error bars denote standard deviation.   
 
Epha4 expression levels in the spinal cord of nontransgenic, Epha4+/- and Epha4eGFP/+ were 
compared. Using a C-terminal Epha4 antibody, Epha4+/- mice and Epha4eGFP/+ mice had 
similar levels of the Epha4 cytoplasmic domain, which are 50% compared to the Epha4 levels 
in nontransgenic animals (Figure 2.3A,C). Next, we determined to what extent Epha4 
phosphorylation was affected in the heterozygous Epha4eGFP/+ mouse. Replacement of the 
Epha4 wild type protein by the Epha4eGFP isoform removes the kinase domain and the 
phosphorylation sites present in the kinase domain and the juxtamembrane region. We 
focused on the phosphorylation levels of Y779, located in the kinase domain of the Epha4 
receptor. Phosphorylation of Y779 was comparable in the Epha4eGFP/+ mice and the Epha4+/- 
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mice, but reduced compared to nontransgenic animals (Figure 2.3B,D). These results indicate 
that Epha4 expression and phosphorylation status is similar in Epha4eGFP/+ and in Epha4+/- 
mice.  
 
 
Figure 2.3 Phosphorylation levels of Epha4 in the spinal cord of Epha4+/-, Epha4eGFP/+ and 
nontransgenic mice. (A, C) Epha4 expression in lumbar spinal cords of Ntg mice (n = 14, 100% 
expression), Epha4+/- mice (n = 8, 61% expression) and Epha4eGFP/+ mice (n = 8, 52% expression). (B, D) 
Phosphorylation of Y779, a Epha4 kinase domain residue, in lumbar spinal cords of Ntg mice (n = 9, 
100% expression), Epha4+/- mice (n = 4, 69% expression) and Epha4eGFP/+ mice (n = 4, 70% expression). 
GAPDH (37 kDa) was used as a loading control. ANOVA tests were used for statistical analysis, 
***p<0.001. Error bars denote standard deviation. 
 
  
 
 
47 
 
2.2.2 Abolishing Epha4 forward signaling in the SOD1G93A mouse model   
 
Epha4eGFP/+ mouse were crossbred with the SOD1G93A mouse model. Replacement of one 
Epha4 allele in the SOD1G93A mouse with an Epha4eGFP isoform, did not affect disease 
onset, assessed by hanging wire and rotarod performance (Figure 2.4A,B). Survival and 
disease duration was unaltered in the Epha4eGFP/+; SOD1G93A mouse, in contrast to the 
Epha4+/-; SOD1G93A which showed a beneficial effect on survival and disease duration (Figure 
2.4C,D)35.  
 
Figure 2.4 Deletion of the Epha4 cytoplasmic domain did not affect disease onset and survival in 
SOD1G3A mice. (A) Disease onset as determined by hanging wire. Median disease onset:  109 d 
(Epha4+/+; SOD1G93A, n = 29) and 109 d (Epha4eGFP/+; SOD1G93A, n = 30). (B) Disease onset as 
determined by rotarod. Median disease onset:  104.5 d (Epha4+/+; SOD1G93A, n = 28) and 106 d 
(Epha4eGFP/+; SOD1G93A, n = 31). (C) Median survival: 155 d (Epha4+/+; SOD1G93A, n = 29) and 157 d 
(Epha4eGFP/+; SOD1G93A, n = 33). (D) Average disease duration as determined by hanging wire or 
rotarod respectively: 47and 50 d (Epha4+/+; SOD1G93A, n = 29), 46 and 51 d (Epha4eGFP/+; SOD1G93A, n = 
30). 
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In order to assess subtle effects on motor neuron degeneration too small to affect the 
clinical status of the animals, we quantified the number of motor neurons in the spinal 
ventral horn, and studied the degree of neuromuscular innervation. Histopathological 
analysis of age-matched mice showed no difference in preserved ventral horn motor 
neurons nor neuromuscular junctions in Epha4eGFP/+; SOD1G93A mice as compared to 
littermate controls (Epha4+/+; SOD1G93A) (Figure 2.5).   
 
 
 
Figure 2.5 Ventral horn motor neurons and neuromuscular junctions were not preserved in the 
Epha4eGFP/+; SOD1G93A mice compared to their age-matched littermate controls (Epha4+/+; SOD1G93A). 
(A) Relative number of small and large motor neurons in the spinal cord of late-
symptomatic Epha4eGFP/+; SOD1G93A mice (n = 3) compared to age-matched Epha4+/+; SOD1G93A 
littermates (n = 5) (B) Percentage completely innervated neuromuscular junctions: 48% (Epha4eGFP/+; 
SOD1G93A, n = 8) versus 50% (Epha4+/+; SOD1G93A, n = 9, age-matched controlled). 
These data show that replacement of one Epha4 allele by an Epha4eGFP isoform did not 
affect disease onset and survival in a mouse model of ALS. Thus, abolishment of Epha4 
forward signaling by deleting the Epha4 cytoplasmic domain did not influence ALS, 
suggesting that it is a reduction of Epha4 reverse signaling that is beneficial for motor 
neuron degeneration in ALS . 
2.2.3 Abolishing Epha4 forward signaling negatively affects the re-innervating capacity of 
motor neurons 
 
Previously, we showed that Epha4 determines the re-innervating capacity of motor neurons 
(Figure 1.3). In general, sprouting of motor neurons is increased when Epha4 is deleted 
and/or blocked 212-213, 217. More specifically, it is thought to be mediated by abolishing Epha4 
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forward signaling 234. We therefore studied the role of Epha4 forward signaling in re-
innervation capacity of the motor neuron by investigating the effect of replacing the Epha4 
cytoplasmic domain with a eGFP protein on neuromuscular re-innervation following 
axotomy of the sciatic nerve. As shown in figure 2.6A, the re-innervation capacity in Epha4 
knockout mice was significantly improved compared to wild type mice. Surprisingly, 
Epha4eGFP/eGFP mice showed reduced re-innervation capacity compared to wild type mice 
(Figure 2.6B). These data show that we have to be cautious to interprete the data of this 
transgenic mouse model as replacement of the Epha4 cytoplasmic domain not only 
abolishes forward signaling, but most likely interferes with different aspects of Epha4 
signaling such as cleavage and clustering.    
 
  
Figure 2.6 Re-innervation of gastrocnemius neuromuscular junctions after sciatic nerve 
axotomy. (A) Re-innervation of gastrocnemius neuromuscular junctions after sciatic nerve 
axotomy in Epha4+/+ (n = 11) and Epha4−/− mice (n = 8, OR 2.014 ± [1.675–2.422]). (B) Re-
innervation of gastrocnemius neuromuscular junctions after sciatic nerve axotomy 
in Epha4+/+ (n = 13) and Epha4eGFP/eGFP mice (n = 8, OR 0.423 ± [0.332–0.539]). ****p<0.0001. 
OR, Odds ratio 
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2.3 Discussion 
 
Interaction between Eph receptors and ephrin ligands can result in bidirectional signaling, 
meaning forward signaling in the Eph-bearing cell and reverse signaling in the cell that 
expresses the ephrin ligand. Deletion of one Epha4 allele in the SOD1G93A mouse model 
abolishes both forward and reverse signaling, thereby increasing survival in these mice 35. 
Furthermore Epha4-/- mice showed enhanced re-innervation capacity following axotomy of 
the sciatic nerve. To investigate whether the hazardous effect of Epha4 on ALS and the re-
innervation capacity after sciatic nerve axotomy is mediated through forward or reverse 
signaling, we used the Epha4eGFP/eGFP mouse in which the cytoplasmic domain has been 
replaced by an enhanced Green Fluorescent Protein (eGFP) 206.  
Replacement of one Epha4 allele in the SOD1G93A mouse with an Epha4eGFP isoform, did not 
affect survival even though deletion of one Epha4 allele did increase survival (Figure 2.7) 35. 
Thus, it appears that reverse rather than forward signaling underlies the pathogenic 
contribution of Epha4 in ALS. Although negative outcomes are always difficult to rely upon, 
we do think this conclusion is valid in view of the large number of mice that we used in these 
experiments. Furthermore, we excluded subtle effects on the disease by investigating the 
number of remaining motor neurons and neuromuscular innervation.  
Still, our observation needs to be interpreted with caution. First, we only used heterozygous 
Epha4eGFP/+ mice as homozygous Epha4eGFP/eGFP mice have a rabbit-like hopping gate making 
it difficult to assess motor performance 206. Furthermore, we found that the replacement of 
the intracellular domain of Epha4 by eGFP results in increased abundance of this hybrid 
molecule. This is also evident from the blots that have been published when this mouse was 
reported 206. There may be several reasons for this.  Epha4 can be cleaved both by MMPs 
and by γ-secretases yielding Epha4 extra- and intracellular domains 201, 237. This cleavage of 
Epha4 is important for the modulation of its expression and function 238. Removal of the 
intracellular domain might impair proper cleavage of Epha4 thereby altering its expression 
level, as we observed. In addition, complete removal of the intracellular domain also 
abolishes the SAM-domain, which is involved in receptor clustering, which may affect 
processing of the receptors. Finally, the Eph receptors are endocytosed resulting in 
breakdown of the receptor in lysosomes 239. In this way the duration and intensity of 
downstream signaling can be regulated. It has been shown that Epha4 can indeed be 
endocytosed 240-241. Removal of the cytoplasmic domain in the Epha4eGFP isoform might 
interfere with this process of endocytosis and termination of signaling. Because of the 
increased abundance of the Epha4eGFP, it is possible that its reverse signaling is actually 
enhanced, in addition to its forward signaling being reduced.  
That replacing the intracellular Epha4 domain with eGFP may have effects other than just 
blocking the forward signaling is also suggested by the results of our axotomy experiments. 
It has been shown that Epha4 plays a negative role in sprouting of neurons. Epha4 is 
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upregulated in axonal stumps after injury 212 and in sprouting neurons of aged mice after 
stroke which contributes to reduced recovery 217. Furthermore, blocking Epha4 induced 
more sprouting after spinal cord injury 210. It is generally accepted that this negative effect 
on sprouting can be assessed in vitro by studying the inhibiting (collapsing) effect of ephrin 
ligands on the axonal growth cone. Growth cone collapse by stimulation with ephrin ligands 
is thought to be mediated by Epha4 forward signaling through the kinase function as this 
collapse could not be induced in Epha4eGFP/eGFP neurons and in Epha4KD/KD neurons in which 
the kinase domain has been mutated 234. As these data indicate that Epha4 regulation of 
sprouting is mediated through forward signaling, we investigated the re-innervation capacity 
of Epha4eGFP/eGFP mice following sciatic nerve axotomy. Surprisingly, we found that 
Epha4eGFP/eGFP mice showed reduced re-innervation capacity following sciatic nerve axotomy 
while in Epha4-/- mice this re-innervation capacity was enhanced 35. These data suggest that 
in the Epha4eGFP/eGFP mouse in vivo, the outgrowth enhancing effect of deleting the forward 
signaling, is abolished by the outgrowth inhibiting effect generated through the remaining 
reverse signaling, which is likely to be even further enhanced because of the increased 
abundance of the EphA4eGFP molecule as explained above. 
Therefore, to confirm our conclusion that the hazardous effect of Epha4 on ALS is mediated 
through reverse signaling, it is of interest to investigate the effect of a more subtle inhibition 
of forward signaling on ALS. This can be done by studying the Epha4KD/KD mouse 242. In this 
mouse model the kinase domain is not functional by the replacement of the critical lysine 
residue K653 by a methionine. So far all functions mediated through Epha4 forward signaling 
are thought to be mediated through the kinase domain, as no functions have been assigned 
to the SAM domain and the PDZ domain 242-243. This Epha4KD/KD mouse model has some 
advantages over the Epha4eGFP/eGFP mouse. In the Epha4KD/KD mouse only one amino acid has 
been replaced, while in the Epha4eGFP/eGFP mouse the whole intracellular domain has been 
replaced. In this way no other domains involved in cleavage, clustering or endocytosis will be 
mutated. Crossbreeding of the Epha4KD/KD mouse with the mutant SOD1 mouse is being 
done in our lab. However, even in this experiment, we still have to be cautious to interprete 
these results as in the heterozygous Epha4KD/+ mouse which will be used to cross with the 
mutant SOD1 mouse, the Epha4KD isoform can still be phosphorylated through 
crossphosphorylation of the Epha4 wild type allele that is present. In the Epha4+/- and the 
Epha4eGFP/+ mice this crossphosphorylation is not possible as there is less Epha4 receptor or 
less Epha4 intracellular domain respectively. Homozygous EphA4KD/KD transgenic mice may 
solve the problem but are almost impossible to obtain, as we also experienced with the 
homozygous ephA4 knockout mice.   
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Chapter 3. The role of ephrin ligands in ALS  
 
All experiments performed by Lies Schoonaert. Vessel permeability assay in collaboration with 
Thomas Mathivet 
3.1 Introduction  
 
Epha4 is a promiscuous receptor, interacting with both ephrina and ephrinb ligands. Reverse 
signaling through interaction of Epha4 with both ephrin A and ephrin B ligands has been 
reported. The formation of the anterior commissure of the forebrain depends on Epha4 
reverse signaling through ephrinb2 242, 244. Furthermore, long-term potentiation is mediated 
through reverse signaling involving the interaction of Epha4 on the motor neurons and 
ephrina3 on the astrocytes 205. Since our data suggest reverse signaling to be involved in the 
modifying effect of Epha4 on ALS pathogenesis, we intended to determine which Epha4 
ligands might be involved in this process. 
Reverse signaling can occur through interaction of Epha4 with ephrin ligands on surrounding 
cells such as muscle cells, astrocytes, microglia and oligodendrocytes 245. At the 
neuromuscular junction, Epha4 can interact with ephrina1, ephrina2, ephrina5 and ephrinb1 
246-247. In the CNS, ephrina1, ephrina3, ephrina5, ephrinb1 and ephrinb2 have been identified 
in oligodendrocyte precursor cells and in mature oligodendrocytes 248-250. Ephrina5 and 
ephrinb2 are upregulated during oligodendrocyte differentiation 248. Astrocytes express 
ephrina2, ephrina3, ephrina5 and ephrinb2 251-252. Ephrina3 has a crucial function in synaptic 
plasticity as it is involved the regulation of hippocampal dendritic spine morphology and 
regulates the abundance of glial glutamate transporters 205, 253-255. Astrocytic ephrinb2 
regulates adult hippocampal neurogenesis and is highly upregulated in reactive astrocytes 
after spinal cord lesions 252, 256-257. Ephrina5 is highly upregulated in astrocytes at the peri-
lesioned area after experimental stroke 218. Since our data suggest reverse signaling to be 
involved in the modifying effect of Epha4 on ALS pathogenesis, we intended to study the 
Epha4 ligands which may be involved in this process.  
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3.2 Results 
3.2.1 Expression profile of ephrin ligands in the SOD1G93A mouse 
 
As Epha4 interacts with ephrina ligands as well as ephrinb ligands, we investigated 
expression of all ephrin ligands in spinal cord of SOD1G93A mice at different time points 
during the disease progression using qPCR. Different ligands showed different changes 
during disease progression. Expression of ephrina2, ephrina3, ephrina5 and ephrinb2 
decreased at end stage (Figure 3.1B,C,E,G). Ephrina1, ephrina4, ephrinb1 and ephrinb3 did 
not change expression during disease course (Figure 3.1A,D,F,H).  
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Figure 3.1 Expression profile of ephrin ligands in the spinal cord of nontransgenic, SOD1WT and 
SOD1G93A mice. (A) Quantitative RT-PCR of ephrina1 in ventral spinal cords of nontransgenic mice at 
P200 (n = 5, 100% expression), SOD1WT mice at P200 (n = 5, 102% expression) and SOD1G93A mice at 
P90 (n = 5, 64% expression), P145 (n = 5, 58% expression) and ES (n = 5, 49% expression). (B) 
Quantitative RT-PCR of ephrina2 in ventral spinal cords of nontransgenic mice at P200 (n = 5, 100% 
expression), SOD1WT mice at P200 (n = 5, 85% expression) and SOD1G93A mice at P90 (n = 5, 51% 
expression), P145 (n = 5, 29% expression) and ES (n = 5, 18% expression). (C) Quantitative RT-PCR of 
ephrina3 in ventral spinal cords of nontransgenic mice at P200 (n = 5, 100% expression), SOD1WT mice 
at P200 (n = 5, 88% expression) and SOD1G93A mice at P90 (n = 5, 50% expression), P145 (n = 5, 23% 
expression) and ES (n = 5, 13% expression). (D) Quantitative RT-PCR of ephrina4 in ventral spinal 
cords of nontransgenic mice at P200 (n = 6, 100% expression), SOD1WT mice at P200 (n = 6, 78% 
expression) and SOD1G93A mice at P90 (n = 6, 204% expression), P145 (n = 6, 146% expression) and ES 
(n = 6, 98% expression). (E) Quantitative RT-PCR of ephrina5 in ventral spinal cords of nontransgenic 
mice at P200 (n = 5, 100% expression), SOD1WT mice at P200 (n = 6, 106% expression) and SOD1G93A 
mice at P90 (n = 5, 101% expression), P145 (n = 4, 71% expression) and ES (n = 6, 65% expression). (F) 
Quantitative RT-PCR of ephrinb1 in ventral spinal cords of nontransgenic mice at P200 (n = 5, 100% 
expression), SOD1WT mice at P200 (n = 5, 148% expression) and SOD1G93A mice at P90 (n = 5, 84% 
expression), P145 (n = 5, 56% expression) and ES (n = 5, 67% expression). (G) Quantitative RT-PCR of 
ephrinb2 in ventral spinal cords of nontransgenic mice at P200 (n = 6, 100% expression), SOD1WT 
mice at P200 (n = 6, 133% expression) and SOD1G93A mice at P90 (n = 6, 138% expression), P145 (n = 
6, 104% expression) and ES (n = 6, 91% expression). (H) Quantitative RT-PCR of ephrinb3 in ventral 
spinal cords of nontransgenic mice at P200 (n = 5, 100% expression), SOD1WT mice at P200 (n = 5, 
96% expression) and SOD1G93A mice at P90 (n = 5, 67% expression), P145 (n = 5, 35% expression) and 
ES (n = 5, 29% expression). ANOVA tests were used for statistical analysis, *p<0.05. Error bars denote 
standard deviation. RT-PCR, Real-Time Polymerase Chain Reaction; ES, End Stage 
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3.2.2 Expression profile of ephrinb2 
  
In view of the pathogenic role of astrocytes in ALS and the fact that astrocytes are known to 
confer a hazardous effect in ALS, we focused on the ephrin ligands expressed by the 
astrocytes, and in particular on ephrinb2, as it is expressed both on resting and reactive 
astrocytes 252, 256. Furthermore, there is evidence that astrocytic ephrinb2 affects recovery 
from spinal cord injury 256-257. This improved recovery was correlated with an increased 
regenerative capacity of sprouting spinal cord axons 212, 257.  
To investigate the role of ephrinb2 in the pathogenesis of ALS, we first studied the ephrinb2 
expression profile in spinal cords of wild type SOD1 and mutant SOD1 mice. Ephrinb2 
immunoreactivity was present in neurons and oligodendrocytes in SOD1WT and SOD1G93A, as 
shown by its colocalisation with the neuronal marker Neuronal-specific nuclear protein 
(NeuN) and the oligodendrocytic marker Mouse Monoclonal APC antibody (cc1) (Figure 3.2 
and 3.3). Ephrinb2 expression was not detected in microglia, as shown by absence of its 
colocalisation with the microglial marker Cluster of Differentiation Molecule 11B (cd11b) 
(Figure 3.4). Interestingly, in the spinal cord of end stage SOD1G93A mice, ephrinb2 expression 
was prominently present in reactive astrocytes, which is in accordance with high ephrinb2 
expression in reactive astrocytes after spinal cord lesions (Figure 3.5) 256-257.  
In mutant SOD1G93A mice ephrinb2 was expressed in the nucleus of astrocytes at P60 and 
P90 (Figure 3.6A). From P120 on ephrinb2 was highly expressed in the nucleus and the 
processes of reactive astrocytes. Ephrinb2 was present in neurons at all stages (Figure 3.6B). 
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Figure 3.2 Motor neurons in the spinal cord of end stage SOD1G93A mice and age-matched SOD1WT 
mice express ephrinb2. Ephrinb2 was co-stained with the neuronal marker, NeuN, in the spinal cord 
of SOD1WT (150 d) and end stage SOD1G93A mice.  
 
 
Figure 3.3 Oligodendrocytes in the spinal cord of end stage SOD1G93A mice and age-matched 
SOD1WT mice express ephrinb2. Ephrinb2 was co-stained with the oligodendrocytic marker, cc1, in 
the spinal cord of SOD1WT (150 d) and end stage SOD1G93A mice.  
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Figure 3.4 Microglia in the spinal cord of end stage SOD1G93A mice and age-matched SOD1WT mice 
do not express ephrinb2. Ephrinb2 was co-stained with the microglial marker, cd11b, in the spinal 
cord of SOD1WT (150 d) and end stage SOD1G93A mice. 
 
 
Figure 3.5 Reactive astrocytes in the spinal cord of end stage SOD1G93A mice ephrinb2. Ephrinb2 was 
co-stained with the neuronal marker, GFAP, in the spinal cord of SOD1WT (150 d) and end stage 
SOD1G93A mice. Resting astrocytes in the spinal cord of SOD1WT mice only showed faint 
immunoreactivity in their nucleus, but reactive astrocytes in the spinal cord of end stage SOD1G93A 
mice expressed ephrinb2 both in their cell bodies and their processes. 
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Figure 3.6 Ephrinb2 expression in astrocytes and motor neurons over disease progression in the 
SOD1G93A mouse model. (A) At P60 and P90 ephrinb2 showed weak expression in the nucleus of 
astrocytes, while it was highly expressed in the nucleus and the processes of reactive astrocytes from 
P120 on. Co-labeling was performed with ephrinb2 (red) and the astrocytic marker GFAP (green). (B) 
Ephrinb2 was expressed in motor neurons during the disease course. Co-labeling was performed with 
ephrinb2 (red) and the neuronal marker NeuN (green). 
 
In order to investigate whether these mice data are of relevance for human ALS, we studied 
ephrinB2 expression in the spinal cord of ALS patients and controls. As shown in figure 3.7, 
ephrinB2 expression was found to be present in motor neurons in the spinal cord of controls 
and of ALS patients. Interestingly, reactive astrocytes present in the spinal cord of ALS 
patients abundantly expressed ephrinB2 (Figure 3.7) much alike what we observed in the 
mutant SOD1 mouse model.  
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Figure 3.7 EphrinB2 was expressed in motor neurons and reactive astrocytes in spinal cord of ALS-
patients and controls. Neuronal expression was shown by DAB-staining of the neuronal marker 
Smi32 in control and ALS spinal cord. GFAP expression was detected in resting astrocytes in control 
spinal cord and in reactive astrocytes in ALS spinal cord. EphrinB2 expression was observed in 
neurons in control and ALS spinal cord and in reactive astrocytes in ALS spinal cord. DAB, 3,3' 
diaminobenzidine tetrahydrochloride  
 
 
In SOD1G93A mice, ephrinb2 mRNA expression in the spinal cord was somewhat variable 
during the disease course; expression was lowest at P140, slightly increasing again during 
end stage disease (Figure 3.8C). These small fluctuations were not apparent at the protein 
level (Figure 3.9). mRNA and protein levels of ephrinb2 were unaltered in nontransgenic and 
SOD1WT mice at similar time points (Figure 3.8A,B and figure 3.9).   
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Figure 3.8 Expression profile of ephrinb2 in the spinal cord of nontransgenic, SOD1WT and SOD1G93A 
mice. (A) Quantitative RT-PCR of ephrinb2 in ventral spinal cords of nontransgenic mice at different 
ages: P60 (n = 5, 100% expression), P90 (n = 6, 104% expression), P120 (n = 6,109% expression) and 
P140 (n = 9, 95% expression). (B) Quantitative RT-PCR of ephrinb2 in ventral spinal cords of SOD1WT 
mice at different ages: P60 (n = 4, 100% expression), P90 (n = 4, 103% expression), P120 (n = 5, 101% 
expression) and P140 (n = 5, 102% expression). (C) Quantitative RT-PCR of ephrinb2 in ventral spinal 
cords of SOD1G93A mice at different ages:  P60 (n = 7, 100% expression), P90 (n = 5, 83% expression), 
P120 (n = 7, 79% expression), P140 (n = 4, 59% expression) and ES (n = 4, 70% expression). ANOVA 
tests were used for statistical analysis, *p<0.05. Error bars denote standard deviation. RT-PCR, Real-
Time Polymerase Chain Reaction; ES, End Stage 
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Figure 3.9 Expression profile of ephrinb2 in the spinal cord of nontransgenic, SOD1WT and SOD1G93A 
mice. (A,D) Western blot for ephrinb2 on ventral spinal cords of nontransgenic mice at different 
ages: P60 (n = 5, 100% expression), P90 (n = 5, 99% expression), P120 (n = 5, 83% expression), P140 
(n = 5, 71% expression). (B,E) Western blot for ephrinb2 on ventral spinal cords of SOD1WT mice at 
different ages: P60 (n = 4, 100%) , P90 (n = 4, 103% expression), P120 (n = 4, 113% expression) and 
P140 (n = 3, 103% expression). (C,F) Western blot for ephrinb2 on ventral spinal cords of SOD1G93A 
mice at different ages: P60 (n = 4, 100% expression), P90 (n = 4, 87% expression), P120 (n = 4, 77% 
expression), P140 (n = 4, 82% expression) and ES (n = 4, 74% expression)) at different ages. GAPDH 
(37 kDa) was used as loading control (Figure A,B,C). Error bars denote standard deviation; ES, End 
Stage 
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3.2.3 Effect of ephrinb2 on ALS in the SOD1G93A mouse model 
 
To assess the role of ephrinb2 in the pathogenesis of ALS, we studied the effect of deletion 
of ephrinb2 in the SOD1G93A mouse model. As the ephrinb2-/- mouse is embryonically lethal 
with major cardiovascular defects, we used the ephrinb2 conditional knockout mouse 
(Figure 3.10A) 258. In this mouse model exon two of the ephrinb2 gene is flanked by loxP sites 
and will be excised when the Cre enzyme is present and active (Figure 3.10A). To ascertain 
that ephrinb2 levels are not altered by the insertion of the loxP sites we performed 
quantitative real-time PCR on brain and spinal cord of efnb2+/+, efnb2fl/+ and efnb2fl/fl mice; 
as expected no differences in ephrinb2 RNA levels were observed (Figure 3.10B,C).  
 
Figure 3.10 The ephrinb2 conditional knockout mouse. (A) Schematic representation of the 
ephrinb2 conditional knockout mouse (B) Quantitative RT-PCR of ephrinb2 in lumbar spinal cords of 
efnb2+/+ mice (n = 3, 100% expression), efnb2fl/+ mice (n = 4, 105% expression) and efnb2fl/fl mice (n = 
4, 93% expression). (B) Quantitative RT-PCR of ephrinb2 in brains of efnb2+/+ mice (n = 3, 100% 
expression), efnb2fl/+ mice (n = 4, 103% expression) and efnb2fl/fl mice (n = 4, 91% expression). Error 
bars denote standard deviation. RT-PCR, Real-Time Polymerase Chain Reaction 
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3.2.4 Effect of selective deletion of ephrinb2 from astrocytes in the SOD1G93A mouse model 
 
As ephrinb2 expression is upregulated in reactive astrocytes, we investigated whether 
deletion of ephrinb2 from reactive astrocytes influences disease progression in ALS. To this 
end, we used a GFAPCre mouse in which Cre is expressed in astrocytes from E14.5 on 259. 
Therefore, our laboratory assessed the selectivity of the GFAPCre system by crossbreeding 
this GFAPCre mouse with an enhanced Yellow Fluorescent Protein (eYFP) reporter mouse 260. 
In this reporter mouse the eYFP cDNA was preceded by a loxP-flanked stop sequence. YFP 
expression showed highest expression in astrocytes as expected, but was also expressed in 
neurons and oligodendrocytes (A. Nonneman et al. unpublished results). These findings 
suggest that in the efnb2fl/fl; GFAP mouse ephrinb2 expression is not exclusively reduced in 
astrocytes, but also in other cell types.  
Therefore we used the Cx30CreER mouse which expresses the Cre enzyme in astrocytes only 
261. In the spinal cord of Cx30CreER mice crossed with the eYFP reporter mouse, YFP 
expression was present specifically in the astrocytes (A. Nonneman et al. unpublished 
results). High recombination efficiency was detected as almost all astrocytes showed YFP 
expression.  
  
In the Cx30CreER mouse expression of the CreER fusion protein can be induced after 
administration of Tamoxifen (Tx). We crossbred the homozygous ephrinb2 conditional 
knockout mice with the Cx30CreER and the SOD1G93A mouse. All mice were treated with Tx 
60 days after birth (P60). To assess deletion of ephrinb2, we compared the ephrinb2 protein 
expression in spinal cord lysates of efnb2fl/fl; Cx30; SOD1G93A and efnb2fl/fl; SOD1G93A 20 days 
after Tx administration (P80) and at end stage. No difference in ephrinb2 expression was 
detected between efnb2fl/fl; Cx30; SOD1G93A mice and efnb2fl/fl; SOD1G93A mice at P80, which 
is probably explained by the fact that astrocytes only weakly express ephrinb2 early in the 
disease (Figure 3.13A,B). However, at ES, when astrocytes abundantly express ephrinb2, a 
clear decrease in ephrinb2 protein expression was observed in efnb2fl/fl; Cx30; SOD1G93A mice 
(Figure 3.13C,D).  
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Figure 3.13 Ephrinb2 excision in lumbar spinal cord in efnb2fl/fl; SOD1G93A mice and efnb2fl/fl; Cx30; 
SOD1G93A mice at P80 and end stage (A,B) Western blot of ephrinb2 in lumbar spinal cords of 
efnb2fl/fl; SOD1G93A mice at P80 (n = 5, 100% expression) and efnb2fl/fl; Cx30; SOD1G93A mice at P80 (n = 
5, 83% expression, p = 0.3804). (C,D) Western blot of ephrinb2 in lumbar spinal cords of efnb2fl/fl; 
SOD1G93A mice at ES (n = 5, 100% expression) and efnb2fl/fl; Cx30; SOD1G93A mice at ES (n = 5, 72% 
expression, p = 0.0573). GAPDH was used as loading control. Error bars denote standard deviation; 
ES, End Stage 
 
We then investigated the effect of this selective deletion of ephrinb2 from the astrocytes on 
disease onset and survival in the SOD1G93A mouse. Onset as assessed by hanging wire test 
was not different in efnb2fl/fl; Cx30; SOD1G93A mice as compared to efnb2fl/fl; SOD1G93A mice 
(Figure 3.14A). Unexpectedly, deletion of ephrinb2 from astrocytes worsened disease: 
disease duration was shortened by not less than 34% (efnb2fl/fl; SOD1G93A (34d) and efnb2fl/fl; 
Cx30; SOD1G93A (22.5 d) p = 0.0482) (Figure 3.14B) and survival was decreased (Average 
survival: efnb2fl/fl; SOD1G93A (166d) and efnb2fl/fl; Cx30; SOD1G93A (157 d) p = 0.0297) (Figure 
3.14C,D). Overall, deleting ephrinb2 specifically from astrocytes aggravated the ALS 
phenotype.  
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Figure 3.14 Astrocytic deletion of ephrinb2 with the Cx30CreER mouse did not influence disease 
onset, but decreased the survival in SOD1G3A mice. (A) Disease onset as determined by hanging wire. 
Median disease onset:  133 d (efnb2fl/fl; SOD1G93A, n = 24) and 135 d (efnb2fl/fl; Cx30; SOD1G93A, n = 
24). (B) Average disease duration as determined by hanging wire: 34 d (efnb2fl/fl; SOD1G93A, n = 24), 23 
d (efnb2fl/fl; Cx30; SOD1G93A, n = 24, p = 0.0482). (C,D) Average survival: 166 d (efnb2fl/fl; SOD1G93A, n = 
24) and 157 d (efnb2fl/fl; Cx30; SOD1G93A, n = 24) p = 0.0297. *p < 0.05. Error bars denote standard 
deviation. 
 
To better understand this unexpected result, we investigated whether deleting ephrinb2 
from astrocytes affects the glial population: astrocytes, microglia, NG2 glia and 
oligodendrocytes, all known to play a role in ALS. To do so, we studied the mRNA levels of 
several glial markers in whole spinal cord lysates of efnb2fl/fl; Cx30; SOD1G93A and efnb2fl/fl; 
SOD1G93A mice at P80 and at ES. As expected, the mRNA levels of astrocytic (Glial Fibrillary 
Acid Protein (GFAP) and 10-formyltetrahydrofolate dehydrogenase (Aldh1l1)), microglial 
(CX3C Chemokine Receptor 1 (CX3CR1)) and oligodendrocyte precursor (Neural/glial antigen 
2 (NG2)) markers were increased and the oligodendrocytic marker Myelin Basic Protein 
(MBP) was significantly decreased at end stage compared to P80 mice (Figure 3.15). 
Interestingly, efnb2fl/fl; Cx30; SOD1G93A mice at end stage showed decreased levels of GFAP 
mRNA, a reactive astrocyte marker, compared to efnb2fl/fl; SOD1G93A mice (Figure 3.15A). 
This difference was not seen for Aldh1l1, a general astrocyte marker (Figure 3.15B). 
Surprisingly, the mRNA level of the microglial marker CX3CR1 was highly upregulated in 
efnb2fl/fl; Cx30; SOD1G93A mice compared to efnb2fl/fl; SOD1G93A mice (Figure 3.15C). The 
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mRNA level of NG2 was not different between efnb2fl/fl; Cx30; SOD1G93A and efnb2fl/fl; Cx30; 
SOD1G93A mice (Figure 3.15D). MBP expression was decreased in efnb2fl/fl; Cx30; SOD1G93A 
mice at end stage compared to efnb2fl/fl; SOD1G93A mice (Figure 3.15E). Thus, reduced 
astrocytic ephrinb2 expression resulted in a decrease expression of GFAP, a marker for 
reactive astrocytes expression, and MBP, an oligodendrocyte marker, and an increase in 
CX3CR1, a marker for microglia. 
 
Figure 3.15 Quantitative RT-PCR analyses of glia-related molecules in the lumbar spinal cord of 
efnb2fl/fl; SOD1G93A and efnb2fl/fl; Cx30; SOD1G93A mice. (A) Quantitative RT-PCR of GFAP in lumbar 
spinal cords of efnb2fl/fl; SOD1G93A mice at P80 (n = 4, 100% expression) and ES (n = 4, 580% 
expression), and efnb2fl/fl; Cx30; SOD1G93A mice at P80 (n = 4, 87% expression) and ES (n = 4, 484% 
expression); two-way ANOVA, both age and genotype factor are statistically significant, t-test age p = 
0.0215. (B) Quantitative RT-PCR of Aldh1l1 in lumbar spinal cords of efnb2fl/fl; SOD1G93A mice at P80 (n 
= 4, 100% expression) and ES (n = 4, 166% expression), and efnb2fl/fl; Cx30; SOD1G93A mice at P80 (n = 
4, 110% expression) and ES (n = 4, 154% expression); two-way ANOVA, only age factor is statistically 
different. (C) Quantitative RT-PCR of CX3CR1 in lumbar spinal cords of efnb2fl/fl; SOD1G93A mice at P80 
(n = 4, 100% expression) and ES (n = 4, 159% expression), and efnb2fl/fl; Cx30; SOD1G93A mice at P80 (n 
= 4, 87% expression) and ES (n = 4, 191% expression); two-way ANOVA, both age and genotype are 
statistically significant, t-test ES p = 0.0069. (D) Quantitative RT-PCR of NG2 in lumbar spinal cords of 
efnb2fl/fl; SOD1G93A mice at P80 (n = 4, 100% expression) and ES (n = 4, 109% expression), and 
efnb2fl/fl; Cx30; SOD1G93A mice at P80 (n = 4, 118% expression) and ES (n = 4, 140% expression); two-
way ANOVA, only genotype factor is statistically significant. (E) Quantitative RT-PCR of MBP in lumbar 
spinal cords of efnb2fl/fl; SOD1G93A mice at P80 (n = 4, 100% expression) and ES (n = 4, 65% 
expression), and efnb2fl/fl; Cx30; SOD1G93A mice at P80 (n = 4, 94% expression) and ES (n = 4, 48% 
expression); two-way ANOVA, both age and genotype factor are statistically significant, t-test ES p = 
0.0434. Each result was normalized with qBase to 18s, GAPDH and polr2a. *p < 0.05, **p < 0.01, ***p 
< 0.001. Error bars denote standard deviation. RT-PCR, Real-Time Polymerase Chain Reaction; ES, End 
Stage 
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To explain how impairing astrocyte function through astrocyte-specific deletion of ephrinb2 
worsens ALS, we considered the role ephrinb2 plays in the sprouting of endothelial cells 262-
263. Ephrinb2 might have a similar effect in astrocytes on the motility and morphology of its 
processes. As one functions of the astrocytes is the establishment and maintenance of the 
BBB with their so-called endfeet, we hypothesized that loss of ephrinb2 from astrocytes may 
impair the integrity of the blood brain barrier, which then may contribute to worsening  of 
the disease. BBB integrity was assessed by perfusing efnb2fl/fl; Cx30CreER and efnb2fl/fl mice 
two to three months after tamoxifen administration with Evans blue fluorescent dye. 
Leakage of the dye into the parenchyma was used as a measure for BBB leakiness. 
Extravasation of dye in the brain of efnb2fl/fl; Cx30CreER mice clearly exceeded that in 
efnb2fl/fl mice (Figure 3.16). These data suggest that deletion of ephrinb2 from the astrocytes 
impairs the integrity of the BBB.  
 
 
Figure 3.16 Evans blue quantification in the brain of efnb2fl/fl and efnb2fl/fl; Cx30 mice. Two hours 
after Evans blue intravenous injection efnb2fl/fl (n = 5) and efnb2fl/fl; Cx30 (n = 8) mice were sacrificed 
and intracardially perfused with 2% PFA solution. Evans blue quantity was calculated using a standard 
curve. A significant increase was detected in the brain of efnb2fl/fl; Cx30 mice. *p < 0.05. Error bars 
denote standard deviation. PFA, paraformaldehyde 
 
To further elucidate this in the context of ALS, we investigated the BBB integrity in SOD1G93A 
mice at different time points during the disease progression. Increased BBB leakage and 
Blood Spinal Cord Barrier (BSCB) leakage was detected in brain and in spinal cord in SOD1G93A 
mice during disease progression while no leakage was detected in age-matched SOD1WT 
mice (Figure 3.17A,B). Deletion of ephrinb2 from astrocytes in SOD1G93A mice further 
increased BBB leakiness in brain as well as in spinal cord (Figure 3.17C,D). The increased 
leakage was already detectable at P100-110, to further increase at P140.  
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Figure 3.17 Evans blue quantification in brain and spinal cord. Two hours after Evans blue 
intravenous injection mice were sacrificed and intracardially perfused with 2% PFA solution. Evans 
blue quantity was calculated using a standard curve. (A) Evans blue extravasation in brain of SOD1WT 
mice at P140 (n = 5, mean = 1.00) and SOD1G93A mice at P60 (n = 4, mean = 1.12), P80 (n = 3, mean = 
0.96), P100 (n = 6, mean = 1.67) and P140 (n = 4, mean = 2.01). (B) Evans blue extravasation in spinal 
cord of SOD1WT mice at P140 (n = 5, mean = 1.00) and SOD1G93A mice at P60 (n = 4, mean = 1.32), P80 
(n = 3, mean = 1.25), P100 (n = 6, mean = 1.54) and P140 (n = 4, mean = 1.92). (C) Evans blue 
extravasation in brain of efnb2fl/fl; SOD1G93A mice at P100 – 110 Cx30Cre negative (n = 4, mean = 1.00) 
and Cx30Cre positive (n = 5; mean = 1.42) and efnb2fl/fl; SOD1G93A mice at P140 Cx30Cre negative (n = 
4, mean = 1.00) and Cx30Cre positive (n = 5; mean = 2.16). (D) Evans blue extravasation in spinal cord 
of efnb2fl/fl; SOD1G93A mice at P100 – 110 Cx30Cre negative (n = 4, mean = 1.00) and Cx30Cre positive 
(n = 5; mean = 1.46) and efnb2fl/fl; SOD1G93A mice at P140 Cx30Cre negative (n = 4, mean = 1.00) and 
Cx30Cre positive (n = 5; mean = 2.00). p < 0.05; **p < 0.01. Error bars denote standard deviation. 
PFA, paraformaldehyde 
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3.3 Discussion 
 
In this chapter, we explored the potential role of ephrin ligands in the pathogenesis of ALS. 
We quantified all ephrins in the spinal cord of the SOD1G93A mouse, and although the 
expression of some ephrins temporarily increased with disease progression, no consistent 
pattern emerged. We therefore concentrated on astrocytic ephrins, more specifically on 
ephrinb2. We found ephrinb2 to be expressed in neurons, oligodendrocytes and astrocytes. 
We detected high ephrinb2 expression in the neurons in the spinal cord of adult SOD1WT and 
SOD1G93A mice which is in agreement with high ephrinb2 RNA expression in isolated cortical 
neurons of P7 mice 264. This neuronal expression decreased during disease progression as 
motor neurons degenerate. The astrocytic ephrinb2 expression also changed with disease 
progression in the SOD1G93A mouse model. At P60 and P90 ephrinb2 showed weak nuclear 
expression in astrocytes while from P120 on ephrinb2 was detected throughout the 
astrocytes, including its processes. The expression of ephrinb2 in reactive astrocytes has 
already been reported 256-257. mRNA and protein levels of ephrinb2 did not show major 
changes over disease progression in the SOD1G93A mouse model, which can be explained by a 
decreased neuronal expression as neurons degenerate and an upregulated expression in 
reactive astrocytes.   
To delete ephrinb2 from reactive astrocytes we intended to use the GFAPCre mouse in 
which Cre is expressed in astrocytes from E14.5 on 259. However, as previously reported in 
the CNS GFAP is not only expressed in astrocytes, but also in ependymal cells 265. In our 
laboratory we showed GFAP to be present mainly in astrocytes, but also in neurons and 
oligodendrocytes (A. Nonneman et al., unpublished results). In addition, outside the central 
nervous system GFAP could also be detected in kidney, testis, skin, bone, pancreas and liver 
266-269. Therefore we used the Cx30CreER mouse which expresses the Cre enzyme only in 
astrocytes 261. In the spinal cord Cx30 was present specifically in astrocytes (A. Nonneman et 
al., unpublished results). Outside the CNS, expression of Cx30 has also been detected in the 
ear and in the skin, but deletion of Cx30 did not affect hearing and did not cause skin 
disorders 270-271. Thus, the Cx30CreER mouse is a suitable mouse model to study the effect of 
astrocyte specific deletion of ephrinb2 on the disease progression in ALS.  
Astrocyte-specific deletion of ephrinb2 in the SOD1G93A mouse did not affect disease onset, 
but aggravated the disease. Current experiments are being done to support this worsening 
in terms of motor neuron counts and neuromuscular innervation. This worsening of the 
clinical disease progression was associated with evidence for increased severity at the 
molecular level, as shown by increased microglial activation and oligodendrocytic 
dysfunction. Although it is possible that increased CX3CR1 and decreased MBP reflect faster 
progression of the disease, it is possible that these molecular changes are directly induced by 
the lack of ephrinb2 in astrocytes and thus the cause of the faster progression. Indeed, 
astrocytes affect microglial activation, and are a supplier of lactate providing metabolic 
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support to the oligodendrocytes. Thus, clinical as well as biochemical analysis demonstrate 
that astrocyte-specific deletion of ephrinb2 worsens ALS.   
Previously we showed that Epha4 reverse signaling through ephrin ligands at least partially 
contributes to the effect of Epha4 in ALS. As Epha4 is mainly expressed on motor neurons, it 
interacts with ephrin ligands on surrounding cells including astrocytes, microglia and 
oligodendrocytes 35. As ephrinb2 is highly expressed on reactive astrocytes, which play an 
important role in the pathogenesis of ALS, we hypothesized that the effect of Epha4 in ALS is 
at least partially mediated through its interaction with astrocytic ephrinb2. We expected 
that reducing astrocytic ephrinb2 levels thereby abolishing its interaction with neuronal 
Epha4 would result in a protective effect. Counterintuitively we found a decrease in survival 
when ephrinb2 is deleted in the astrocytes, suggesting that the effect of Epha4 in ALS is not 
mediated though astrocytic ephrinb2 signaling. However, we have to be cautious when 
interpreting these results. Next to Epha4, ephrinb2 interacts with several EphB receptors of 
which EphB4 is the most important one 149. Deleting ephrinb2 from the astrocytes will 
abolish the interaction with Epha4, but also with other Eph receptors which might negatively 
influence the pathogenesis of ALS. To elucidate whether ephrinb2 reverse signaling is 
involved in the effect of Epha4 in the pathogenesis of ALS, we would have to block 
specifically the interaction between Epha4 and ephrinb2, which is difficult to accomplish 
because of the presence of other interaction partners for both Epha4 and ephrinb2.   
Absence of ephrinb2 can obviously affect multiple functions of the astrocyte. One such 
function is the establishment of the blood brain barrier. The BBB consists of endothelial cells 
surrounded by pericytes and astrocytes. Astrocytes are important regulators in the 
development and maintenance of the BBB through their so-called their endfeet 272. 
Astrocyte-specific deletion of ephrinb2 induced BBB leakage in adult mice. In the mouse ALS 
model as well as in humans, a leaky BBB has been demonstrated before and astrocytic 
endfeet are known to be swollen and dissociated from the endothelium 273-275. We found 
that deleting ephrinb2 from astrocytes enhanced the existing BBB leakiness in mutant SOD1 
mice. The finding that this increase is evident already early in the disease, and that leakiness 
is also found in the absence of mutant SOD1, suggests that the increased BBB permeability in 
the astrocytic ephrinb2 deleted mice is not just a reflection of enhanced disease progression. 
However, further investigation is needed to elucidate whether BBB impairment is a direct 
consequence of astrocytic ephrinb2 deletion or a secondary phenomenon. The 
morphological basis for this abnormality requires electronmicroscopic evaluation of the 
endothelial-pericytic-astrocytic tripartite and is currently being carried out in our laboratory.  
These data show that the BBB plays a role in the pathogenesis of ALS. BBB impairment has 
been observed in mutant SOD1 animal models as well as in ALS patients 276. In mutant SOD1 
mice the BBB breakdown can be detected prior to motor neuron degeneration and 
inflammation. Furthermore, reduced levels of tight junction proteins and microhemorrhages 
were observed before alterations in inflammation could be detected 277.  However, the 
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specific cause of BBB in the pathogenesis of ALS has not been identified and further 
investigation is needed to elucidate whether BBB impairment is a initial factor or a 
secondary phenomenon.  
In conclusion, deletion of ephrinb2 from astrocytes worsens ALS. Thus, ephrinb2 is unlikely 
to be the ligand through which Eph4 contributes to ALS. Our findings demonstrate that loss 
of ephrinb2 from astrocytes impairs BBB function and enhanced BBB leakiness at least 
partially contributes to the hazardous effect of astrocytic ephrinb2 deletion on ALS.  
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Materials and methods  
 
1. Animal housing, breeding, evaluation and experiments 
 
Animal housing and ethics statement  
 
Mice were housed in the ‘KU Leuven’ animal facilities with a 12 h light-dark cycle at a 
temperature of 20 °C. Animals were given free access to standard rodent chow and water 
and were helped with their food and fluid intake at the end of their disease. All animals 
received care in accordance to The Principles of Laboratory Animal Care formulated by the 
National Society for Medical Research and the Guide for the Care and Use of Laboratory 
Animals published by the National Institutes of Health (NIH publication no. 86-23, revised 
1996). Protocols were designed to minimize animal discomfort and all experiments were 
approved by the Ethical Committee for Animal Research of the University of Leuven, 
Belgium. 
 
Animals 
Epha4-/- mice (C57/Bl6J background) were generated as previously described 236 and were 
kindly provided by Professor A.M. Turnley (University of Melbourne, Victoria, Australia). 
Both the EphA4eGFP/eGFP mouse (C57/Bl6J background) as well as the conditional ephrinb2 
knockout mouse (efnb2fl/fl, official name: Efnb2<tm4Kln>, C57/Bl6J background) were 
generated as previously described 206 and were kindly provided by Professor R. Klein (Max-
Planck-Institute of Neurology, Munich, Germany). The Cx30CreER mouse (Tg(Gjb6-cre/ERT2), 
C57/Bl6J background) was generated as previously described 261 and was kindly provided by 
Professor Dr. F.W. Pfrieger (European Neuroscience Institute, Strasbourg, France). 
Transgenic mice overexpressing wild type human SOD1 [B6SJL-Tg(SOD1)2Gur/J; stock 
number: 002297] and mutant human SOD1 [B6SJL-Tg(SOD1*G93A)1Gur/J; stock number: 
002726] as well as the CAGGCreER mouse (B6.Cg-Tg(CAG-cre/Esr1*)5Amc/J; stock number: 
004682) were purchased from Jackson Laboratory. GFAPCre mice (B6.Cg-Tg(GFAP-
cre)8Gtm/Nci; stock number: 01XN3) were purchased from the Mouse Repository.  
 
Evaluation of mice 
Three times a week motor performance was evaluated with the rotarod test and the hanging 
wire test. For the rotarod test, a rotarod treadmill (Ugo Basile, Varese, Italy) rotating at 15 
rpm during 300 s was used. Each mouse was given three trials of 300 s, three times a week 
starting at 60 days after birth. Disease onset was defined as the time point when rotarod 
performance was reduced with more than 50%. Disease onset by the hanging wire test was 
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defined as the time point at which the mouse failed to hang upside down for at least one 
min on a grid one meter above a soft surface. End stage of the disease was determined as 
the inability to turn around within 30 s after placement on their back. At this moment the 
mouse was scarified and this time point was considered as the time of death. Late-
symptomatic stage was considered as the time point when mice could not sustain the 
hanging wire test for more than 2 s. At this time point all littermates were sacrificed for 
pathology. 
 
Sciatic nerve axotomy. 
Sciatic nerve axotomy was performed on Epha4+/+, Epha4+/− and Epha4−/− mice. After 
anesthesia with 3% isoflurane, a small incision was made unilaterally at midthigh level. 
Muscles were separated to visualize and transect the sciatic nerve. Afterwards, muscle and 
skin were sutured separately. Twenty days after sciatic nerve axotomy, the gastrocnemius 
muscle was instantly frozen in cooled isopentane (VWR, Paris, France) upon dissection and 
stored at -80°C for further analysis. 
 
Vessel permeability assay (BBB leakage) 
Mice were anesthetized and injected intravenously with 100 μl 1% Evan's blue solution 
(Sigma-Aldrich, St. Louis, USA). Two h after injection, mice were sacrificed and intracardially 
perfused with a 2% paraformaldehyde (PFA) (VWR, Paris, France) solution. Dissected brains 
were weighed and incubated in a formamide (Sigma-Aldrich, St. Louis, USA) solution at 56°C 
for 24 h to extract the dye. The absorbance of the solution was measured with the Victor 
Multilabel Plate Reader (PerkinElmer, Zaventem, Belgium) at 620 nm. The amount of Evans 
Blue is calculated using a standard curve. Data were expressed as fold increase compared to 
wild type animals with weight normalization.  
 
2. Histopathology 
 
Neuromuscular junction staining 
After embedding the muscles in Tissue-Tek O.C.T compound (Sakura, Antwerp, Belgium), 20 
μm thick longitudinal sections were made. Sections were washed twice with 1X Phosphate 
Buffered Saline (PBS) (Sigma-Aldrich, St. Louis, USA) for 5 min and blocked with 5 % normal 
donkey serum (Sigma- Aldrich, St. Louis, USA) in PBST (PBS with 0.1% Triton X-100(Sigma- 
Aldrich, St. Louis, USA, T8787)) for 1 h at room temperature. To visualize neuromuscular 
junctions, sections were simultaneously incubated with Alexa-555-conjugated 
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α‐bungarotoxin (1/5,000, Invitrogen, Carlsbad, CA, B35451) and Alexa-488-conjugated NF-
200 (1/500, Cell Signaling Technologies, Danvers, MA, USA, #80245) diluted in PBST for 2 h at 
room temperature. Sections were washed twice with PBST for 5 min and mounted with 4',6-
diamidino-2-phenylindole (DAPI)-containing Vectashield (Vectorlabs Inc., Burlinglame, CA). 
Fluorescent stains were visualized with a Zeiss Axio Imager M1 microscope (Carl Zeiss, Jena, 
Germany), using the monochrome AxioCam Mrm camera. At least 200 neuromuscular 
junctions were analysed for each mouse. 
 
Cresyl violet staining 
Spinal cords were dissected, fixed in 4% paraformaldehyde (PFA, VWR, Paris, France) and 
cryoprotected in 30% sucrose (Sigma-Aldrich, St. Louis, USA, S0389) in 1x PBS (Sigma-Aldrich, 
St. Louis, USA). After embedding the spinal cords in Tissue-Tek O.C.T compound (Sakura, 
Antwerp, Belgium), fresh frozen sections (20µm) were cut on a cryostat (Leica, Wetzlar, 
Germany) and every tenth slide was captured, in total 10 slides per animal. First, sections 
were hydrated for 3 min in 100% EtOH (VWR, Paris, France), 3 min in 95% EtOH, 3 min in 
70% EtOH and immersed with cresyl violet acetate for 5 min (0.5%, Sigma-Aldrich, St. Louis, 
USA), followed by rehydration for 20s in 70% EtOH with 0.1% acetic acid, 3 min in 95% EtOH, 
3 min in 100% EtOH and three times 3 min in 100% Histoclear (National Diagnostics, Georgia, 
USA, HS-200). Motor neurons were visualized with a Zeiss Axio Imager M1 microscope (Carl 
Zeiss, Jena, Germany) using the monochrome AxioCam Mrc5 camera. The number of 
neurons in different size groups was calculated using Axiovision 4 software (Zeiss, Jena 
Germany) thereby normalizing to the area of normal appearing neurons in the ventral horn. 
Neurons with a cell body area >250 µm² were considered motor neurons. 
 
3. Laser capture microdissection 
 
Cresyl violet staining 
Mice were anesthetized with 10 % Nembutal (Ceva chemicals, Hornsby, NSW, Australia) and 
were transcardially perfused with 1X PBS (Sigma-Aldrich, St. Louis, USA). The lumbar spinal 
cord was dissected and embedded in Tissue-Tek OCT compound (Sakura, Antwerp, Belgium). 
Frozen sections (20µm) were cut on a cryostat (Leica, Wetzlar, Germany) and mounted on 
1.0 PEN membrane slides (Zeiss, Göttingen, Germany). First, sections were hydrated for 3 
min in 100% EtOH (VWR, Paris, France), 3 min in 95% EtOH, 3 min in 70% EtOH and 
immersed with cresyl violet acetate for 5 min (0.5%, Sigma-Aldrich, St. Louis, USA), followed 
by rehydration for 20s in 70% EtOH with 0.1% acetic acid, 3 min in 95% EtOH and 3 min in 
100% EtOH.  
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Laser capture microdissection 
Laser capture microdissection is a method to isolate the cells of interest under direct 
microscopic visualization 278. A laser is coupled to the microscope and focuses on the spinal 
cords mounted on 1.0 PEN membrane slides (Zeiss, Göttingen, Germany). Ventral horn 
neurons of the lumbar spinal cord with a cell body area larger than 250 µm2 were considered 
as motor neurons and microdissected using a laser capture microdissection system (Zeiss, 
Göttingen, Germany). The outline of the motor neurons was predefined by the user and cut 
out with the laser after which the sample is sucked up and captured in adhesive caps 
(Adhesive Cap 500 opaque, Zeiss, Göttingen, Germany). At least 1,500 motor neurons were 
collected for each condition.  
 
Quantitative real-time PCR 
Total RNA was extracted from the captured motor neurons using the TRIPURE method 13. 
RNA concentrations were determined by a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, DE, USA). cDNA was synthesized from 1 µg of total RNA using the 
Superscript III polymerase according to manufacturer’s instructions (Invitrogen, Carlsbad, 
CA). Quantitative Real-Time PCR reactions were performed using TaqMan Universal PCR 
master mix (Applied Biosystems, Foster city, CA, USA, 4305719) and commercially available 
TaqMan gene expression assays against EphA4 (Invitrogen, Carlsbad, CA, Mm01256005_m1) 
and Polr2a (Invitrogen, Carlsbad, CA, USA, Mm00839502_m1). Thermal cycling was 
performed on the 7900HT Fast and the Step One Plus (AB) Real-time PCR system (Applied 
Biosystems, Foster city, CA, USA) using a standard amplification protocol.  
 
4. Molecular Biology 
 
Western Blot 
All mice were anesthetized with 10 % Nembutal (Ceva chemicals, Hornsby, NSW, Australia). 
Mouse spinal cords, hippocampi and cortices were dissected and homogenised in RIPA lysis 
buffer (Sigma-Aldrich, St. Louis, USA) with proteinase (cOmplete; Roche, Vilvoorde, Belgium) 
and phosphatase inhibitors (phosphostop; Roche, Vilvoorde, Belgium) using the 
MagnNaLyser (Roche, Vilvoorde, Belgium). Protein concentration was determined using the 
Micro-BCA assay (Thermo Scientific, Breda, Nederland, 23235). Freshly made 8% SDS-PAGE 
gels (GFP blots) or 10% SDS-PAGE gels (ephrinb2 blots) were used for electrophoresis. 
Fifteen or twenty microgram was loaded for each sample. After SDS-PAGE the gel was 
transferred to Immobilon-P membrane (Millipore, Overijse, Belgium, IPVH00010) and 
subsequently blocked with 10% Bovine Serum Albumin (Serva, Heidelberg, Germany, 11930) 
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for 1 h at room temperature. As primary antibodies N-terminal mouse anti-EphA4 (1/1,000; 
ECM Biosciences, Lexington, USA, EM2801), chicken anti-GFP (1/1,000; Aves labs, Tigard, 
USA, GFP-1020), mouse C-terminal EphA4 (1/500; Invitrogen, Carlsbad, CA, 37-1600), mouse 
β-actin (1/10,000; Sigma-Aldrich, St. Louis, USA, A2228), goat anti-ephrinb2 (1/500, R&D, 
Abingdon, UK, AF496), rat anti-GFAP (1/1,000; Invitrogen, Carlsbad, CA, 13-0300) and mouse 
anti-GAPDH (1/5,000, Thermo Scientific, Breda, Nederland, AM4300) were used. As 
secondary antibodies anti-mouse-HRP (horse radish peroxidase), anti-rabbit-HRP, anti-goat-
HRP (all 1/5,000; DAKO, Heverlee, Belgium) were used. FEMTO ECL (Thermo Scientific, 
Breda, Nederland, 34095) was used as substrate and the signal was detected using LAS4000 
(GE Healthcare, Diegem, Belgium).  
 
Immunoprecipitation 
Mouse spinal cords were dissected and homogenized in RIPA lysis buffer (Sigma-Aldrich, St. 
Louis, USA) supplemented with proteinase (cOmplete; Roche, Vilvoorde, Belgium) and 
phosphatase inhibitors (phosphostop; Roche, Vilvoorde, Belgium) using the MagnNaLyser 
(Roche, Vilvoorde, Belgium). Protein concentration was determined using the Micro-BCA 
assay (Thermo Scientific, Breda, Nederland, 23235). Five µg of mouse anti-EphA4 antibody 
(Invitrogen, Carlsbad, CA, 37-1600) was incubated with 1.5 mg protein G Dynabeads (Life 
Technologies, Merelbeke, Belgium, 10004D) for 10 min at room temperature. One mg of 
CNS lysate was added and samples were rotated for 2h at 4°C. After washing the beads with 
1x PBS, the target antigen was eluted with 20 µl of elution buffer (Life Technologies, 
Merelbeke, Belgium, 10007D) by heating 10 min at 70°C. The eluate was separated on a 
Novex Nupage 4-12% bis tris gel (Life Technologies, Merelbeke, Belgium, NP0321BOX). After 
SDS-PAGE the gel was transferred to Immobilon-P membrane (Millipore, Overijse, Belgium, 
IPVH00010) and subsequently blocked with 10% Bovine Serum Albumin (Serva, Heidelberg, 
Germany, 11930) for 1 h at room temperature. Rabbit phospho-EphA4 (Tyr-799) (1/500; 
ECM Biosciences, Lexington, USA, EP2751) and mouse C-terminal EphA4 (1/500; Invitrogen, 
Carlsbad, CA, 37-1600) were used as primary antibodies and secondary antibodies anti-
mouse-HRP and anti-rabbit-HRP (all 1/5,000; DAKO, Heverlee, Belgium) were used. Femto 
ECL (Thermo Scientific, Breda, Nederland, 34095) was used as a substrate and the signal was 
detected using LAS4000 (GE Healthcare, Diegem, Belgium). 
 
Digital droplet PCR 
Spinal cord RNA was extracted using the TRIPURE method 13. RNA was quantified and 
reverse-transcribed using random hexamer and oligodT priming and Superscript III 
polymerase (Invitrogen, Carlsbad, CA, 18080051). Gene expression assays for ephrinb2 
covering exon 1-2 (IDT, Leuven, Belgium Mm.PT.58.29108694) and β-actin (Applied 
Biosystems, Foster city, CA, USA, 4351315,) and the ddPCRTM Supermix for Probes (no dUTP) 
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(Bio-Rad, Hercules, CA, USA, 186-3025) were used. Samples were subsequently placed into 
the QX200 Droplet Generator (Bio-Rad, Hercules, CA, USA), which uses proprietary reagents 
and microfluidics to partition the samples into 20.000 nanoliter-sized droplets. The droplets 
are transferred to a 96-well plate for PCR-amplification using the T100TM Thermal Cycler 
(Bio-Rad, Hercules, CA, USA). Following PCR amplification of the nucleic acid target in the 
droplets, the samples are placed in the QX200 Droplet Reader (Bio-Rad, Hercules, CA, USA), 
which analyzed each droplet individually. With the QuantaSoftTM software the PCR-positive 
and PCR-negative droplets are counted and analyzed.  
 
Quantitative real-time PCR 
Spinal cord RNA was extracted using the TRIPURE method 13. RNA was quantified and 
reverse-transcribed using random hexamer and oligodT priming and Superscript III 
polymerase (Invitrogen, Carlsbad, CA,  18080051). For quantitative real-time PCR TaqMan 
gene expression assays for ephrinb2 covering exon 1-2 (IDT, Leuven, Belgium, 
Mm.PT.58.29108694), ephrinb2 covering exon 4-5 (IDT, Leuven, Belgium, 
Mm.PT.58.7363143), 18s (Invitrogen, Carlsbad, CA, USA, Mm04277571_s1), polr2a (IDT, 
Leuven, Belgium, Mm.PT.39a.22214849), GAPDH (IDT, Leuven, Belgium, Mm.PT.39a.1), GFAP 
(IDT, Leuven, Belgium, Mm.PT.58.10570926) and the TaqMan Fast Universal PCR Master Mix 
(Applied Biosystems, Foster city, CA, USA, 4352042) were used. SYBR Green assays were run 
for Aldh1l1 (Fw primer GCAGGTACTTCTGGGTTGCT, Rv primer GGAAGGCACCCAAGGTCAAA), 
NG2 (Fw primer AGGCTGAGGTAAATGCTGGG, Rv primer GCAGGTGGTGAGGACAGTAG), 
CX3CR1 (Fw primer CGTGAGACTGGGTGAGTGAC, Rv primer GGACATGGTGAGGTCCTGAG) 
and MBP (Fw primer CATCCTTGACTCCATCGGGC, Rv primer CAGGGTACCTTGCCAGAGC), 
using the Fast SYBR Green Master Mix (Applied Biosystems, Foster city, CA, USA, 4385618). 
All primers are ordered at IDT, Leuven, Belgium. Expression levels were normalised to 
polr2a, GAPDH and 18s using qBase. Thermal cycling was performed on the Step One Plus 
(AB) Real-time PCR systems (Applied Biosystems, Foster city, CA, USA). Each reaction was 
done in triplicate.  
 
5. Stainings 
 
Immunostaining 
Spinal cords were dissected, fixed in 4% paraformaldehyde (PFA, VWR, Paris, France) and 
cryoprotected in 30% sucrose (Sigma-Aldrich, St. Louis, USA, S0389) in 1x PBS (Sigma-Aldrich, 
St. Louis, USA). After embedding the spinal cords in Tissue-Tek O.C.T compound (Sakura, 
Antwerp, Belgium), fresh frozen sections (20µm) were cut on a cryostat (Leica, Wetzlar, 
Germany). Co-labeling was established by immunostaining for goat anti-ephrinb2 (1/75 
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overnight at 4°C, Neuromics, Edina, Minnesota, USA, GT15026-100), mouse anti-NeuN 
(1/200 1h room at temperature (RT), Millipore, Overijse, Belgium, MAB377), mouse anti-
GFAP (1/500 1h at RT, Invitrogen, Carlsbad, CA, USA, A-21282), anti-cc1 (1/200 1h at RT, 
Abcam, Cambridge, Massachusetts, USA, Ab16794), rat anti-cd11b (1/200 1h at RT, AbD 
Serotec, Bio-rad, Hercules, CA, USA, MCA618R) and anti-iba1 (1/200 1h at RT, WAKO, 
Richmond, USA, 019-19741). After incubation with primary antibodies, the slides were 
washed three times with PBST and consequently incubated with Alexa-488/555 labeled 
secondary antibodies (1/500 1h at RT, Invitrogen, Carlsbad, CA, USA). All slides were washed 
twice with PBST for 5 min and once with PBS for five min, and mounted with Prolong® Gold 
Antifade Mountant with DAPI (Thermo Scientific, Breda, Nederland, P36935). Pictures were 
taken with the Leica SP8x confocal microscope (Leica, Diegem, Belgium). 
 
DAB staining 
After embedding the human spinal cords in Tissue-Tek O.C.T compound (Sakura, Antwerp, 
Belgium), fresh frozen sections (20µm) were cut on a cryostat (Leica, Wetzlar, Germany). 
Tissue was fixed for 15 min with 4% paraformaldehyde (PFA, VWR, Paris, France). 
Endogenous peroxidases were blocked by incubating the slides for 30 min with 0.3% H2O2 
(VWR, Paris, France) in 50% MeOH (VWR, Paris, France). Samples were incubated with goat 
anti-ephrinb2 (1/75 overnight 4°C, Neuromics, Edina, Minnesota, USA, GT15026-100), mouse 
anti-smi32 (1/200, Covance, Princeton, NJ, USA, SMI-32R) and sheep anti-GFAP (1/500 1h at 
RT, Abcam, Cambridge, Massachusetts, USA, ab90601). After incubation with primary 
antibodies, the slides were washed three times with PBST and consequently incubated with 
biotinylated secondary antibodies (1/500 1h RT, DAKO, Heverlee, Belgium). The signal is 
amplified using an avidin-biotin peroxidase complex and visualised with 3,3' 
diaminobenzidine tetrahydrochloride (DAB) (Vectastain ABC kit, Vectorlabs Inc., Burlinglame, 
CA). Pictures were taken with a Zeiss Axio Imager M1 microscope (Carl Zeiss, Jena, Germany) 
using the monochrome AxioCam Mrc5 camera. 
  
80 
 
  
 
 
81 
 
Part 2.  Exploration of the therapeutic potential of 
EphA4 inhibitors 
Introduction  
 
EphA4 has been found to play a role in cancer biology and in the pathogenesis of several 
neurological disorders 279. It is upregulated in spinal cord injury, traumatic brain injury and 
stroke, and blocking the receptor increases functional recovery in models for these 
conditions 208, 210, 219. Interestingly, inhibition of EphA4 improves LTP defects in a mouse 
model for AD and improves outcome in animal models for ALS 228, 280-281. The finding that 
EphA4 expression is inversely correlated with survival in ALS patients, suggests that EphA4 is 
involved in human pathology as well 281. These findings suggest that EphA4 inhibition opens 
perspectives for treatment of neurological disorders.  
Inhibition of EphA4 signaling can be obtained through targeting the adenosine triphosphate 
(ATP)-binding pocket in the kinase domain or by blocking the interaction with ephrin ligands 
282-283. Because the ATP-binding pocket is highly conserved among tyrosine kinases, it is very 
difficult to develop specific inhibitors. Targeting the ligand-binding domain on the other 
hand allows the development of more selective compounds, but poses several problems. 
One of these is the large protein interaction surface to be covered (for EphA4 more than 900 
A²) 284-285, and the dynamic nature of the ligand-binding domain, as EphA4 adapts a 
conformation like other EphA receptors to interact with ephrina ligands and like EphB 
receptors to interact with ephrinb ligands 144, 146, 286.  
So far, two classes of EphA4 binding site antagonists have been described (Table 1): a family 
of benzoic acid derivates, of which the so-called C1 compound is the most studied one, and 
peptidergic antagonists. Of the peptidergic antagonists, the dodecapeptide KYL (named after 
its first three amino acids) has been extensively studied in vitro and in vivo 222. It has been 
reported to have beneficial effects in spinal cord injury and in ALS models similar to that 
seen when Epha4 is knocked down genetically 213, 222, 281, 287. However, peptidergic inhibitors 
have limited potency and/or are not stable 283. The KYL peptide has a KD value of 
approximately 1 µM and a very short half-life in serum (11 min in mouse serum) 222, 287. An 
EphA4 inhibitor with higher potency, the cyclic peptide APY-βAla8.am has been reported 
recently, but is awaiting further characterization 284. All other EphA4 inhibitors lack 
specificity and block EphA4 activation at higher concentrations only (micromolar range) 
(Table 1) 282, 288-289.  
In the present chapter, we first have explored the potential of the small compound C1, an 
antagonist that targets both EphA4 and EphA2 290, and of which we previously showed that it 
corrects the phenotype in the zebrafish ALS model. Second, we have used Nanobody 
technology in order to generate selective and stable Epha4 antagonists 291-292. Nanobodies 
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(Nbs) are small antigen-binding fragments derived from camelid heavy-chain antibodies that 
are devoid of light chains. They are superior to conventional antibodies in terms of stability, 
solubility and immunogenicity 291. Furthermore, they are much smaller than conventional 
antibodies (12-15 kDa vs. 150-160 kDa) and can penetrate small clefts and cavities 293. We 
generated Nbs against the ligand-binding domain of the EphA4 receptor. 
 
 
 
Table 1. Overview of known EphA4 inhibitors. ND = not determined. For all compounds and 
peptides all properties concerning specificity, interaction and activity are indicated. Three 
compounds are able to inhibit EphA4 in the micromolar range. Five peptides can inhibit EphA4 in 
micromolar range with cAPY peptide in nanomolar range.   
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Chapter 4. Exploring the use of existing EphA4 inhibitors in ALS 
 
Experiments in collaboration with Division of Pharmaceutical Analysis, KU Leuven 
4.1 Introduction 
We aimed to explore the use of existing EphA4 inhibitors in animal models for ALS. Several 
EphA4 inhibitors have been published in literature, but many of them are not very selective 
(Table 1). We explored the in vivo use of compound 1 (C1), a 2-hydroxy-4(2,5-dimethyl-1-
pyrrol-1-yl)benzoic acid derivative (Figure 4.1).  
  
Figure 4.1 Structure of compound 1 (C1). 
In a high throughput screen 10,000 compounds from the DIVERSetTM library (ChemBridge, 
Inc.) were tested and 43 compounds were able to inhibit the binding between the KYL-
peptide and the EphA4 receptor 290.  One compound was also able to inhibit the binding of 
EphA4 to ephrina5. Fourtynine additional compounds belonging to the same class of 2,5-
dimethylpyrrolyl benzene derivatives were tested of which two were able to inhibit the 
binding of EphA4 both to the KYL-peptide and to ephrina5. Compound 1 binds into the high 
affinity ephrin-binding channel of the EphA4 ligand-binding domain, thereby inhibiting the 
binding of ephrin ligands, except for ephrina4 and ephrinb2 290, 294. Stimulation of the 
hippocampal cell line HT22 with preclustered ephrina5 induces EphA4 phosphorylation, 
which can be inhibited in a dose-dependent way by C1 290. Furthermore, the ephrin system 
has inhibitory effects on axonal outgrowth, which can be assessed in vitro by studying their 
inhibiting (collapsing) effect on the axonal growth cone. Neuronal stimulation with ephrin 
ligands induces this growth cone collapse, which can be inhibited by C1 290. The usefulness of 
this compound has already been shown in previous zebrafish work in our laboratory, in 
which we showed that blocking the EphA4 receptor with C1 could completely rescue the 
axonal phenotype in the zebrafish model of ALS 35.  
Newly synthesized C1 is not active, but when exposed to air and light, C1 undergoes 
spontaneous oxidation forming an active form of C1 thereby acquiring a dark brown color 
295. However, to date the active form of the compound has not been identified 295. 
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4.2 Results 
 
To validate the protective effect of EphA4 inhibition by C1 in other animal models, the 
feasibility of treating SOD1G93A mice with this compound was investigated. A bioanalytical 
method using High Performance Liquid Chromatography (HPLC) with UV detection (HPLC-
UV) was developed to detect and quantify the drug in biological samples. This work was 
performed by Yan Xu, under supervision of Hui Chen, in collaboration with Prof. Dr. A. Van 
Schepdael (Division of Pharmaceutical Analysis, KU Leuven).   
 
 
First, the method was validated using spiked cerebrospinal fluid (CSF) samples (Figure 4.2). 
There was no interference in the chromatogram of CSF matrix at the retention time of C1. 
The retention time of C1 corresponded with the oxidation product of the compound. Next, 
the method was validated for other biological samples (blood, kidney, liver, brain and spinal 
cord), by comparing control samples to spiked samples (data not shown).  
  
 
  
Figure 4.2. Chromatogram of a spiked CSF sample (2) versus control CSF sample (1).   
 
The pharmacokinetics of C1 were determined for nontransgenic mice injected 
intraperitoneally with the compound (50 mg/kg mouse) or the control solution. The 
concentration of C1 decreased very rapidly over time in all tissues evaluated and could no 
longer be detected eight hours after injection (Table 4.1).   
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Time after injection (h) Blood (µg/ml) Kidney (µg/ml) Liver (µg/ml) Brain (µg/ml) Spinal Cord (µg/ml) 
1 75.7 2.13 0.7 0.362 0.437 
4 14.65 <LOQ = 0.589 <LOQ = 0.589 <LOQ = 0.589 <LOQ = 0.589 
8 <LOD = 0.178 <LOD = 0.178 <LOD = 0.178 <LOD = 0.123 <LOD = 0.178 
Table 4.1. Detection of compound 1 at different time points after injection in nontransgenic mice. 
One hour after injection the concentration of the compound could be determined in all tissues. Four 
hours after injection the compound could still be detected, but not quantified. Eight hours after 
injection the concentration of the compound was below the detection limit. (LOD = limit of 
detection, LOQ = limit of quantification)  
 
 
 In a second approach we explored the possibility of continuous administration of C1 into the 
lateral ventricle using mini-osmotic pumps. We determined the stability of C1 in PBS at 37°C 
which revealed rapid degradation of the compound over a few days (Figure 4.3). These data 
indicate that the compound lacks the stability for continuous administration with mini-
osmotic pumps.  
 
 
 
 
Figure 4.3. Stability of C1 in PBS. Concentration of C1 in PBS over time at 37°C as determined with 
HPLC-UV. Error bars denote standard deviation.  
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4.3 Discussion 
  
 
Here we investigated the feasibility to treat SOD1G93A ALS mice with the C1-compound, a 
somewhat selective EphA4 inhibitor. We determined the pharmacokinetics for C1 in 
different tissues after intraperitoneal injection in nontransgenic mice. The concentration of 
C1 rapidly declined over time and was undetectable eight hours after injection, greatly 
limiting the therapeutic potential of C1-IP injection for the treatment of rodent ALS models.  
An alternative approach by delivering the compound directly into the CSF through mini-
osmotic pumps was explored. When treating ALS rodents with mini-osmotic pumps, 
preferentially pumps with long duration (4 weeks) are used to avoid repetitive surgeries, 
requiring the drug administered to be stable over a period of 4 weeks. The concentration of 
C1 in PBS solution at body temperature (37°C) was shown to decline over several days 
precluding the possibility of using it in mini-osmotic pumps.   
The instability of C1 has also been reported elsewhere 295-296. Not only this compound, but 
the whole class of 2,5-dimethyl-pyrrol-1-yl-benzoic acid inhibitors is potentially unstable 
during long-term storage 297. Thus, although C1 is a useful antagonist for certain short-term 
experiments, its chemical instability limits its potential for use in vivo 297.  
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Chapter 5. Identification and characterization of Nanobodies 
specific for the Ephrin A4 receptor 
 
Submitted: Schoonaert et al.   
EphA4 and Nanobody expression in collaboration with the Protein Service Facility (VIB). Nanobody 
generation in collaboration with the Nanobody Service Facility (VIB). Surface Plasmon Resonance in 
collaboration with Bart Roucourt. EphA4 phosphorylation assay in collaboration with Vertex 
Pharmaceuticals. All other experiments performed by Lies Schoonaert with assistance of Mieke 
Timmers. 
 
5.1 Introduction 
 
We explored the potential of Nanobody technology to specifically and potently block EphA4 
signaling 291-292. Nanobodies were discovered more than two decades ago at the Vrije 
Universiteit Brussel 298. Camelids among which camels, llamas and alpacas contain both 
conventional antibodies as well as heavy-chain antibodies (Figure 5.1) 291. Conventional 
antibodies consist of two identical heavy chains and two identical light chains. The N-
terminal variable domain of the heavy chain (VH) and the variable domain of the light chain 
(VL) interact with each other forming the antigen binding site (Figure 5.1). Heavy-chain 
antibodies lack the light chain and the first constant domain, and have some differences in 
the variable domain of the heavy chain (VHH) which are responsible for the association with 
the light chain in conventional antibodies 291. Nanobodies (Nbs) are the isolated VHH 
domains responsible for antigen binding. 
 
Figure 5.1 Antibodies and Nanobodies. The antigen binding sites of conventional antibodies are 
formed by the fusion of VH and VL domains with a flexible linker. Heavy-chain antibodies lack the 
light chain and the first constant domain of conventional antibodies. Their antigen binding site is 
consists of an autonomous single variable domain (VHH). VH, variable domain of heavy chain; VL, 
variable domain of light chain.  
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Nanobodies have many advantages over conventional antibodies. They are much smaller 
than conventional antibodies (12-15 kDa vs. 150-160 kDa) and are superior to conventional 
antibodies in terms of stability, solubility and immunogenicity 291, 293. Nbs are extremely 
stable with a long shelf-life of several months at 4°C, and even longer at  
-20°C and resistance to thermal and chemical denaturation 291. High solubility of Nbs is 
achieved by the presence of hydrophilic amino acids in one of the framework regions299. 
Furthermore, Nbs lack the Fragment crystallizable (Fc) region, which is important for the 
recruitment of immune cells and for effector functions, explaining their limited 
immunogenicity, to which also their small size and their high sequence similarity to human 
VH contribute 291. Of interest, 12 out of 14 amino acids that differ between Nanobody and 
human VH can be humanized thereby diminishing its immunogenicity, a necessary step to be 
accepted as human therapeutics 300. In general, conventional antibodies bind proteins with a 
flat interface, while Nbs can bind and penetrate into small clefts and cavities using their long 
Complementarity Determining Region 3 (CDR3), one of the regions responsible for the 
recognition of the antigen 301.  
Nbs are rapidly cleared from the blood (half-life of 1.5 h or less), and poorly penetrate the 
blood-brain barrier and cell membrane. Of notice, these drawbacks can be overcome 
through chemical modifications (see below). Furthermore, several methods have been 
tested to cross the blood-brain barrier 302.  
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5.2 Results 
5.2.1 Generation of anti-EphA4 LBD Nbs 
 
An alpaca was immunized with recombinant human EphA4 ligand-binding domain (LBD) 
according to standard procedures303. In addition to conventional antibodies, alpacas also 
produce heavy chain only antibodies in response to the recombinant protein. A phagemid 
library was constructed from the RNA from peripheral blood lymphocytes and transformed 
in E. coli TG1 cells. A library of about 2 × 108 independent transformants was obtained and 
about 87% of transformants harbored the vector with the right insert size.  The library was 
subjected to four consecutive rounds of panning, performed on solid-phase coated EphA4 
LBD. The phage population was enriched for antigen-specific phages after 3rd and 4th rounds 
of panning. In total, 190 individual colonies from 3rd and 4th rounds (95 from each round) 
were randomly selected and analyzed by ELISA for the presence of antigen-specific VHHs in 
their periplasmic extracts. In total, 41 colonies (14 and 27 from 3rd and 4th, respectively) 
scored positive in this assay. Sequencing of the VHH genes from 41 positive colonies resulted 
in 15 different Nbs,  belonging to 9 different clonally-unrelated B-cell clones based on 
sequence homology in the complementarity determining region 3 (CDR3) (Figure 5.2). Nbs 
belonging to the same group show very high sequence similarity suggesting they are from 
clonally-related B-cells as a result of hypermutation. Nbs 39, 16, 71, 28 and 22 most likely 
belong to unrelated B-cell clones. Their amino acid sequences are shown in Figure 5.2. Nbs 
are characterized by three complementarity determining regions (CDRs), all contributing to 
antigen binding specificity. The most important differences between clones are mainly 
located in the CDRs (Figure 5.2).  
 
 
 
Figure 5.2 Amino acid sequence of fifteen different anti-EphA4 LBD Nbs. The Nbs have been 
numbered according to Kabat numbering with reference sequence VH3-23/JH5 on top. The 
complementarity determining regions (CDRs) have been assigned according to the AbM definitions 
and are shown with a grey background. The Nbs belong to nine, clonally-unrelated B-cell clones and 
the different groups are shown alternatively in black and purple. According to the amino acid 
sequences Nb 90 and 60, Nb 19 and 57, Nb 34 and 47, Nb 31, 50, 10 and 53 belong to the same 
group. Nb 39, 16, 71, 28, 22 belong to unrelated B-cell clones.  
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5.2.2 Cloning and expression of the anti-EphA4 LBD Nbs 
 
To express and purify the selected Nbs, their genes were subcloned into the pHEN6c 
expression vector, in fusion with a PelB signal leader sequence and a C-terminal His6-tag. The 
pHEN6c vectors were transformed into WK6 E. coli cells enabling the expression of the Nbs 
as a fusion protein with the PelB peptide, directing the expressed protein to the bacterial 
periplasm. The expressed Nbs were extracted from the periplasm by osmotic shock, purified 
using immobilized metal-ion affinity chromatography (IMAC) and gel filtration 
chromatography. The purity of the fractions was analyzed with Coomassie-stained SDS-
polyacrylamide gels and western blot detection using His6-tag (data not shown). All Nbs 
could be detected at a position corresponding to about 15 kDa. There was no contamination 
with other proteins or Lipopolysaccharide (LPS), but there were obvious differences in 
expression levels of the Nbs (Table 5.1) and concentrating the poorly expressed ones 
resulted in protein aggregation. We therefore eliminated Nbs 90, 16, 71, 28 and 10 from the 
screen. The remaining 10 were used for further screening. 
 
  mg Nb per liter of culture 
Nb 90 0.22725 
Nb 60 1.14 
Nb 19 0.6204 
Nb 57 2.33 
Nb 39 3.2 
Nb 16 0.14 
Nb 34 7.29 
Nb 47 0.7812 
Nb 71 0.0945 
Nb 28 0.0585 
Nb 22 18.855 
Nb 31 21.7125 
Nb 50 3.59 
Nb 10 0 
Nb 53 7.7 
 
Table 5.1 Concentration of Nbs expressed in and purified from E. coli. Nb 90, 16, 71, 28 and 10 did 
not yield high concentration and concentrating them led to aggregation.  
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5.2.3 Analysis of EphA4 binding 
 
We next determined whether the Nbs recognised EphA4 under reducing conditions. None of 
them bound recombinant EphA4 (data not shown) on Western Blot; an EphA4 monoclonal 
antibody was used as a positive control and readily bound the recombinant protein. These 
data suggest that the Nbs target a conformational epitope on the EphA4 LBD.   
To test whether the Nbs were indeed able to bind native EphA4, we performed 
immunoprecipitation experiments (Figure 5.3). Nbs 31, 50, 57, 53 and 39 precipitated EphA4 
protein and  EphA4 in turn precipitated these Nbs (data shown for Nbs 53 and 39 in Figure 
5.3A,B). In contrast to the other Nbs, Nanobody 22 showed lower binding to mouse EphA4 
compared to human EphA4 (Figure 5.3C). This is unexpected as the amino acid similarity 
between the LBD of human and mouse EphA4 is over 98%. Nbs 19, 34 and 47 showed non-
specific binding to the beads and to recombinant ephrinb2 (data shown for Nanobody 19 
and 47 in Figure 5.3D,E). Nanobody 60 did not show non-specific binding to the beads, but 
precipitated with recombinant ephrinb2 indicating non-specific binding (Figure 5.3F).   
 
Figure 5.3 Immunoprecipitation of EphA4 with different Nbs (left panel). Immunoprecipitation of 
Nb with EphA4 (right panel). (A,B) Nb 53 and 39 could capture EphA4 and could be captured by 
EphA4. (C) Nb 22 showed lower affinity for mouse EphA4 compared to human EphA4. (D,E) Nb 19 
and 47 showed aspecific binding to the beads. (F) Nb 60 showed aspecific binding to ephrinb2. 
Immunoprecipitation with ephrinb2 (Efnb2) was performed as a control experiment.  
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To identify the Nbs with the highest affinity we determined their binding kinetics to EphA4 
using Surface Plasmon Resonance (SPR). The EphA4 ligand-binding domain (LBD) was 
immobilized onto the chip and Nbs (1 nM to 300 nM) were used as analyte. SPR analysis 
revealed that Nbs 34 and 47 did not bind to the EphA4 LBD (Table 5.2). Nbs (60, 57, 39, 22, 
31, 50) showed binding in low nanomolar range, while Nanobody 19 showed binding in the 
higher nanomolar range only.   
 
We next investigated the affinity of the Nbs for the EphA4 LBD, their affinity for full-length 
recombinant human and for the mouse EphA4 receptor. Most Nbs showed similar binding to 
the full-length receptor as to the EphA4 LBD. Nanobody 31 showed somewhat higher 
binding to the EphA4 LBD than to full length EphA4. Nanobody 22 showed a twofold 
difference in binding affinity between human and mouse EphA4, in agreement with what we 
found in the immunoprecipitation experiments described above (Figure 5.3C). 
Based on these results, we selected seven Nbs (60, 57, 39, 22, 31, 50 and 53) with affinity in 
the nanomolar range for both the EphA4 LBD and the full-length receptor. Nbs 34, 47 and 19 
showed low affinity for EphA4 and were omitted from further analysis. 
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5.2.3 Cross-reactivity with other Eph receptors 
 
The homology between the different Eph receptors is very high. We therefore used 
Alphascreen technology to study the specificity of the Nbs generated. All Eph receptors 
tested showed binding with ephrina5 and/or ephrinb2 indicating that all receptors adapt 
their correct conformation. Ephrina5 interacted with all EphA receptors and with EphB2 as 
has been previously shown (Figure 5.4A) 145. Ephrinb2 interacted with all EphB receptors and 
EphA4, but not with EphB6 for which no ligands have been identified so far (Figure 5.4B) 146, 
304. The control Nanobody did not bind to any of the Eph receptors as expected (data not 
shown).  
  
 
Figure 5.4 Interaction of ephrina5 and ephrinb2 with different Eph receptors. (A) Ephrina5 
interacted with different EphA receptors and with EphB2. (B) Ephrinb2 interacted with different EphB 
receptors and EphA4. Values indicated represent mean with SD 
 
 
Alphascreen analysis showed that Nanobody 60 interacted with several Eph receptors other 
than EphA4 (Figure 5.5A), in agreement with the immunoprecipitation results obtained with 
Nanobody 60 (Figure 5.3F). Nanobody 57 bound EphA4, but also EphA3 and EphA7, and 
Nanobody 50 bound EphA4 but also EphA3, EphA6, EphA7 and EphA8 (Figure 5.5B,F). Nbs 
22, 39, 31 and 53 were almost completely selective for EphA4, although some binding to 
EphA7 was noted (Figure 5.5C, D, E, G). We therefore selected the latter four for further 
screening.  
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Figure 5.5 Cross-reactivity with other Eph receptors (Alphascreen). (A) Next to EphA4 Nb 60 also 
interacted with many other different Eph receptors. (B,C,D,E,F) Nb 57, 22, 39, 31 and 53 had highest 
selectivity to the EphA4 receptor. (F) Nb 50 had low selectivity for EphA4 as it also interacts with 
EphA3, EphA6, EphA7 and EphA8. Error bars denote standard deviation.  
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5.2.4 Competition with ephrin ligands for the interaction with EphA4 
 
EphA4 interacts with most of the ephrins 144, 146. We therefore investigated whether the Nbs 
selected were able to displace these ligands from the EphA4 receptor. We determined the 
optimal concentration for the different ephrin ligands for a fixed concentration of the EphA4 
LBD to avoid the hooking effect (oversaturation of donor and acceptor beads inhibiting their 
association) and added increasing concentrations of the Nbs. The control Nanobody did not 
show any interaction with the different Eph receptors, as expected (data not shown). The 
KYL peptide, a known EphA4 inhibitor was used as a positive control. 
Nb 39 and Nb 53 completely displaced all ephrin ligands from EphA4 binding in a 
concentration range lower than the KYL-peptide (Figure 5.6A-H). Nbs 22 and 31 were less 
potent. Nb 22 completely displaced ephrina3 (Figure 5.6C) and almost completely displaced 
ephrinb ligands (Figure 5.6F, G, H) from EphA4 binding, but no full displacement of the other 
ephrina ligands was obtained with the concentrations tested (Figure 5.6A, B, D, E). Its 
potency was comparable to that of the KYL peptide.  Nanobody 31 completely displaced 
ephrina1, ephrinb1 and ephrinb2 at lower concentrations than the KYL-peptide (Figure 5.6A, 
F, G), completely displaced ephrina3 in concentrations similar to the KYL-peptide (Figure 
5.6C), but ephrina2, ephrina4, ephrina5 and ephrinb3 could not be completely displaced 
with the concentrations tested (Figure 5.6B, D, E). These data show that Nbs 39 and 53 are 
able to block the interaction of all ephrin ligands with the EphA4 ligand-binding domain. 
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Figure 5.6 Inhibition of ligand-binding. (A,D,E,H) Nb 22 and 31 did not show complete inhibition. Nb 
39 and Nb 53 showed complete inhibition of ligand-binding at a lower concentration than the KYL-
peptide. (B,F,G) Nb 22 did not show complete inhibition. Nb 39, Nb 53 and Nb 31 showed complete 
inhibition of ligand-binding at a lower concentration than the KYL-peptide. (C) Nb 39 and 53 showed 
complete inhibition of ligand-binding at a lower concentration than Nb 22, Nb 31 and the KYL-
peptide.  Error bars denote standard deviation.  
 
5.2.5 Inhibition of ephrin-induced EphA4 activation 
 
To assess the antagonistic properties of the Nbs, we tested their effect on ephrin-induced 
phosphorylation. Ephrin-induced phosphorylation was examined using the PathHunter assay 
in U2OS cells. All cells are stimulated with ephrina1 with or without the presence of an 
EphA4 antagonist and the resulting phosphorylation of EphA4 is measured. The control 
Nanobody did not have any effect on receptor phosphorylation (data not shown). The KYL 
peptide showed complete inhibition of ephrina1-induced phosphorylation with an IC50 value 
of 52.96 µM (Figure 5.7). Nbs 39 and 53 also reached complete inhibition of ephrina1-
induced phosphorylation, but at lower concentrations than the KYL-peptide with an IC50 of 
170 nM and 261 nM respectively (Figure 5.7). These data indicate that Nbs 39 and 53 are at 
least ten times more potent than the KYL peptide in ephrina1-induced phosphorylation of 
the EphA4 receptor. 
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Figure 5.7 Inhibition of phosphorylation. Nb 39 and Nb 53 showed complete inhibition of 
phosphorylation at a lower concentration than the KYL-peptide. Error bars denote standard 
deviation.  
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5.3 Discussion 
 
One EphA4 inhibitor, the KYL peptide, has been studied extensively in models for several 
neurological disorders such as acute injuries including spinal cord injury and stroke, and 
neurodegenerative disorders such as ALS and AD 280-281. Unfortunately, this peptide has a KD 
value of approximately 1 µM and a very short half-life in serum (11 min in mouse serum) 222, 
287. Only one very recent study has reported an EphA4 inhibitor with higher potency, the 
cyclic peptide APY-βAla8.am 284, which is yet to be characterized biologically. All other EphA4 
inhibitors lack specificity and need higher concentration (in the micromolar range) to block 
EphA4 activation (Table 1).  
As Nbs are known to be very specific, we used this approach to develop a selective EphA4 
inhibitor targeting the ligand-binding domain. Here, we describe the generation and 
screening of EphA4 inhibitors targeting the LBD based on the Nanobody (Nb) technology. We 
immunized alpacas with the human EphA4 LBD and identified 15 different Nbs against this 
LBD. In a series of experiments, we found Nb 39 and 53 to be at least ten times more potent 
than the KYL peptide with potencies in the nanomolar range. Nb 39 and Nb 53 were most 
selective for EphA4, but still showed considerable binding to EphA7. Interestingly, EphA7 KO 
mice as well as rats treated with EphA7 antisense oligonucleotides show enhanced recovery 
after SCI compared to control mice 305-306. Therefore, targeting EphA7 in addition to EphA4, 
may be of benefit rather than detrimental. This obviously needs further study. 
Conventional antibodies (about 150 kDa) have limited tissue penetration and bind to small 
receptor pockets because of their large size and preference for concave epitopes. Nbs on the 
other hand prefer clefts and small pockets and show higher tissue penetration. However, 
their small size limits their half-life to about 1.5 hours 307. This low half-life can be overcome 
by linking the Nb to a Nb that binds serum albumin which can increase the half-life to 20-30 
h in mice. In humans this strategy was shown to extend the half-life of Nbs to 19 days 308-309. 
Another strategy to increase the half-life is adding polyethyleenglycol (PEG) groups to the 
Nbs, taking care that the PEG groups do not influence the binding to EphA4 310. The addition 
of PEG groups increases the apparent molecular weight above the glomerular filtration limit 
avoiding renal clearance and/or evades cellular clearance mechanisms 311.  
We here describe Nbs targeting the EphA4 ligand-binding domain. Two Nbs were most 
selective for EphA4 and had KD and IC50 values in the nanomolar range. Both Nbs were able 
to block the interaction of EphA4 with all ephrin ligands and inhibit phosphorylation of 
EphA4. Future studies need to investigate whether these promising results can be translated  
in in vitro and in vivo functional models. In addition, the affinity of these Nbs can be further 
increased through error-prone PCR mutagenesis and/or making bispecific Nbs 312-313.    
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Material and Methods 
1. Pharmacokinetics compound 1 
 
Animal housing and ethics statement  
 
Nontransgenic mice with a C57/Bl6J background were purchased from the animal facility. 
Mice were housed in the ‘KU Leuven’ animal facilities with a 12 h light-dark cycle at a 
temperature of 20 °C. Animals were given free access to standard rodent chow and water 
and were helped with their food and fluid intake at the end of their disease. All animals 
received care in accordance to The Principles of Laboratory Animal Care formulated by the 
National Society for Medical Research and the Guide for the Care and Use of Laboratory 
Animals published by the National Institutes of Health (NIH publication no. 86-23, revised 
1996). Protocols were designed to minimize animal discomfort and all experiments were 
approved by the Ethical Committee for Animal Research of the University of Leuven, 
Belgium. 
 
Biodistribution of C1 
Nontransgenic mice were injected intraperitoneally (IP) with C1 (1 mg dissolved in DMSO, 
with 200 μl extra physiological water). Blood sample was saved in a heparin solution (1/10 in 
water) to prevent coagulation. Before organ samples were collected, the mice were perfused 
by 1x PBS (Sigma-Aldrich, St. Louis, USA) to remove all blood from the organs. Each organ 
sample was saved in 2 ml distilled water and homogenized. Sample preparation methods 
and the detection of C1 were optimised and validated in collaboration with the Division of 
Pharmaceutical Analysis, KU Leuven. The work was performed by Yan Xu, under supervision 
of Hui Chen and Prof. Dr. A. Van Schepdael. Briefly, for different samples, different sample 
preparation methods were applied. As the CSF sample has a very low protein content, it can 
be analyzed directly. For blood, liver and kidney samples, protein precipitation was needed. 
For spinal cord and brain samples, Solid Phase Extraction (SPE) was performed, to remove 
interfering matrix components and selectively concentrate the analyte. After sample 
preparation, all samples were analyzed with HPLC-UV.  
 
2. Nanobody screening 
 
Expression and purification of the EphA4 ligand-binding domain   
 
The EphA4 ligand-binding domain (AA 22 – AA 203 according to Singla et al., 2010 286) was 
cloned from the EphA4 Human cDNA ORF clone (Origene) and expressed in the E. coli strain 
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BL21 codon + pICA2 transformed with the pLH36Epha plasmid. Expression is induced by 
isopropyl b-D-1-thiogalactopyranoside under control of a pL-promotor developed by the 
Protein Service Facility of VIB. The pLH36 plasmid is provided with a His6- tag followed by a 
murine caspase-3 site. The murine caspase-3 site can be used for the removal of the His6-tag 
attached at the N terminus of the protein of interest during purification. The transformed 
bacteria were grown in Luria Bertani medium supplemented with ampicillin (100 µg/mL) and 
kanamycin (50 µg/mL) overnight at 28°C before 1/100 inoculation in a 20 liter fermenter 
provided with Luria Bertani medium supplemented with ampicillin (100 µg/mL) and 1% 
glycerol. The initial stirring and airflow was 200 rpm and 1.5 L/min, respectively. Further, this 
was automatically adapted to keep the pO2 at 30 %. The temperature was kept at 28°C. The 
cells were grown to an optical density of A600nm = 1.0, transferred at 20°C, and expression 
was induced by addition of 1 mM isopropyl b-D-1-thiogalactopyranoside overnight. Cells 
were then harvested and frozen at -20°C. After thawing, the cells were resuspended at 3 
mL/g in 20 mM NaH2PO4 pH 7.5, 500 mM NaCl, 20 mM imidazole and 1 mM 
phenylmethylsulfonyl fluoride. The cytoplasmic fraction was prepared by sonication of the 
cells followed by centrifugation at 18,000g for 30 min. All steps were conducted at 4°C. The 
clear supernatant was applied to a 74 mL Ni-Sepharose 6 FF column (GE Healthcare, Diegem, 
Leuven), equilibrated with 20 mM NaH2PO4 pH 7.5, 500 mM NaCl, 20 mM imidazole and 
0.1% CHAPS. The column was eluted with 20 mM NaH2PO4 pH7.4, 20mM NaCl, 400mM 
imidazole and 0.1% CHAPS after an extra wash step with 50 mM imidazole. The elution 
fraction was diluted 1/20 with 20 mM Tris pH 8.0 and 0.1% CHAPS and loaded on a 20-mL 
Source 15Q column (GE Healthcare, Diegem, Leuven) to remove contaminants. After 
equilibration, the protein of interest was eluted by a linear gradient over 20 column volumes 
of NaCl from 0 to 1 M in 20 mM Tris pH 8.0 and 0.1% CHAPS. To the EphA4-containing 
fractions, activated murine caspase-3 (1/100 % m/m murine caspase-3/EphA4) with 10 mM 
DTT was added to remove the His6-tag. After 1 h incubation at 37°C, the reaction solution 
was injected on a HiLoad 26/60 Superdex 75 prep grade with PBS as running solution for 
formulation and to remove minor contaminants, His6-tag and murine caspase-3. The 
obtained fractions were analyzed by SDS-PAGE and the concentration was determined using 
the Micro-BCA assay (Thermo Scientific, Breda, Nederland, 23235).  
 
Construction of a VHH library  
 
Nbs targeting the EphA4 ligand-binding domain (LBD) were obtained in collaboration with 
the VIB Nanobody Service Facility. An alpaca was injected subcutaneously on days 0, 7, 14, 
21, 28 and 35, each time with about 250 µg of human Ephrin A4 LBD. On day 39, 
anticoagulated blood was collected for lymphocyte preparation. A variable domain of heavy-
chain antibodies (VHH) library was constructed and screened for the presence of antigen-
specific Nbs. To this end, total RNA from peripheral blood lymphocytes was used as template 
for first strand cDNA synthesis with oligo(dT) primer. Using this cDNA, the VHH encoding 
sequences were amplified by PCR, digested with PstI and NotI, and cloned into the PstI and 
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NotI sites of the phagemid vector pMECS. A VHH library of about 2 × 10E8 independent 
transformants was obtained. About 87% of transformants harbored the vector with the right 
insert size.  
 
 
Isolation of hEphA4 LBD-specific Nbs  
 
To screen for the presence of EphA4-specific Nbs, the library was subjected to 4 consecutive 
rounds of panning, performed on solid-phase coated EphA4 LBD (concentration: ~200 g/ml, 
~20 g/well). The enrichment for antigen-specific phages after each round of panning was 
assessed by comparing the number of phages eluted from antigen-coated wells with the 
number of phages eluted from negative control (only-blocked) wells. These experiments 
suggested that the phage population was enriched for antigen-specific phages after 3rd and 
4th rounds of panning. In total, 190 individual colonies from 3rd and 4th rounds (95 from each 
round) were randomly selected and analyzed by ELISA for the presence of antigen-specific 
Nbs in their periplasmic extracts (ELISA using crude periplasmic extracts including soluble 
Nbs). Of 190 colonies, 41 colonies (14 and 27 from 3rd and 4th, respectively) scored positive 
in this assay. The selected clones were analysed and their VHH genes were sequenced to 
identify the different Nbs.   
 
Expression and purification of recombinant Nbs  
The Nanobody genes were subcloned into the pHEN6c expression vector, in fusion with a C-
terminal His6-tag. The pHEN6c vectors were transformed into WK6 E. coli cells and grown in 
Luria Bertani medium supplemented with ampicillin (100 µg/mL) and 0.1 % glucose at 37°C 
overnight. Further, the cultures were inoculated  1/100 to have 1 liter productions in Terrific 
Broth medium supplemented with ampicillin (100 µg/mL) and 0.1 % glucose in baffles shake 
flasks. The temperature was kept at 37°C. The cells were grown to an optical density of 
A600nm = 1.0, transferred at 28°C, and expression was induced by addition of 1 mM isopropyl 
b-D-1-thiogalactopyranoside overnight. Cells were then harvested and frozen at -20°C. The 
expressed Nbs were extracted from the periplasm by osmotic shock and purified using His 
GraviTrap (GE Healthcare, Diegem, Belgium) in parallel, equilibrated with 20 mm NaH2PO4, 
pH 7.5, 300 mM NaCl, 20 mM imidazole, and 1 mM PMSF. After loading, the columns were 
washed with 20 column volumes of the same buffer. The  Nanobody was first eluted with 20 
mM NaH2PO4, pH 7.5, 20 mM NaCl, 50 mm imidazole, 1 mM PMSF and then with 400 mM 
imidazole in the same buffer. Finally, the Nbs were desalted to PBS on sephadex G25 (GE 
Heathcare, Diegem, Belgium). The obtained fractions were analyzed with Coomassie-stained 
SDS-polyacrylamide gels. Protein concentration was measured by the Micro-BCA assay 
(Thermo Scientific, Breda, Nederland, 23235).  
 
104 
 
Immunoprecipitation experiments 
One and a half mg protein G Dynabeads (Life Technologies, Merelbeke, Belgium, 10004D) 
were preblocked with 1% BSA for 1 h at room temperature, washed four times with PBS and 
incubated with  2.5 µg of recombinant mouse or human EphA4 protein (R&D, Abingdon, UK, 
641-A4-200 and 6827-A4-050) for 10 min at room temperature. After washing four times 
with PBS the beads were incubated with 1 µg Nanobody overnight at 4°C. The beads were 
washed four times with PBS, boiled for 10 min in reducing sample buffer (Thermo Scientific, 
Breda, Nederland, 39000) and proteins were fractionated with a Novex Nupage 4-12% bis 
tris gel (Life Technologies, Merelbeke, Belgium, NP0321BOX). After SDS-PAGE the gel was 
transferred to Immobilon-P membrane (Millipore, Overijse, Belgium, IPVH00010) and 
subsequently blocked with 10% Blotting-grade blocker (Bio-Rad, Hercules, CA, USA, 
1706404) for 1 h at room temperature. Mouse anti-EphA4 antibody 1/1,000 (ECM 
Biosciences, Lexington, USA, EM2801) and mouse anti-HA antibody 1/1,000 (Covance, 
Princeton, NJ, USA,MMS-101P) were used to detect EphA4 and Nanobody respectively. 
EphA4 was captured with Nanobody anti-HA magnetic Dynabeads (Life Technologies, 
Merelbeke, Belgium, 88837) were used and all following steps were performed as described 
above.  
 
Surface Plasmon Resonance 
The equilibrium dissociation constant (KD) and the association (ka) and dissociation rates (kd) 
were determined using surface plasmon resonance detection on a BIACore T200 (GE 
Healthcare). Two approaches were used. First, the extracellular N-terminal domain of human 
EphA4 was immobilized directly onto a CM5 S series sensor chip (GE Heathcare, Diegem, 
Belgium, BR100530) using standard amine coupling. After activation of the carboxyl moieties 
on the matrix on the chip surface with a 7-min injection of a 1:1 mixture of 0.4 M EDC and 
0.1 M NHS, the N-terminal domain of human EphA4 (50 µg/ml in 10 mM acetate, pH 4.5) 
was immobilized to a predefined level of response units (RU). Approximately 300 RU of N-
terminal domain of human EphA4 was bound onto flow channels. The remaining activated 
carboxyl groups were blocked by injecting 1 M ethanolamine (pH 8.5) for 7 minutes. Flow 
rate was kept constant at 10 µl/min.  A flow channel activated with EDC/NHS and 
immediately afterwards blocked by ethanolamine served as reference channel. Throughout 
the analysis 10 mM Hepes, 150 mM NaCl, 3 mM EDTA, 0.01 mM Surfactant P-20 pH 7.35 was 
used as running buffer. 20 mM glycine pH 2.5 was used to regenerate the channels (remove 
all bound proteins). The second approach used the anti-human Fc capture kit as described by 
the manufacturer. Briefly, approximately 8000 RU anti-human Fc antibody was capture on 
the surface of the channels using amine coupling as described above. In a next step, EphA4-
hFc (both human and mouse EphA4 (R&D, Abingdon, UK, 641-A4-200 and 6827-A4-050) 
fusion protein (2 µg /ml diluted in running buffer) was injected (10 µl/min for 6 minutes) 
over de the channel resulting in the capture of approximately 500 RU of EphA4-hFc fusion 
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protein on the surface of the channel. In this approach, a channel with only anti-human Fc 
antibody served as reference. 3M MgCl2 was used as regeneration buffers. The Nbs were 
diluted to the indicated concentrations in running buffer and injected (60 µl/min) over the 
channel with immobilized EphA4 and the reference channel. After correction of the response 
using the responses from the reference channel and a blank injection of running buffer over 
the Eph4A-immobilized channel (double referencing), kinetic parameters were determined 
using Biacore T200 evaluation software (GE Heathcare, Diegem, Belgium).   
 
Phosphorylation assay 
The amount of phosphorylation of EphA4 was determined using the PathHunter assay 
(DiscoveRx Corporation, Birmingham, UK) with U2OS cells adapted for the EphA4 receptor 
according to manufacters instructions. In short, a small peptide epitope is expressed 
recombinantly on the intracellular C-terminus of the EphA4 receptor tyrosine kinase. An 
interaction partner containing SH2 domains is co-expressed with a larger sequence, termed 
enzyme activator (EA). Ephrina1-induced activation causes dimerisation leading to 
crossphosphorylation. The SH2-EA fusion protein binds the phosphorylated receptor forcing 
the complementation of EA and the peptide epitope, yielding an active β-galactisodase 
enzyme. This interaction can be visualised with a chemiluminscent substrate. Increasing 
concentrations of the Nbs are added to the medium before ephrina1 stimulation.   
EphA4 U2OS cells were plated into white opaque 384-well plates at a volume of 20 µl 
containing 5,000 cells. After short centrifugation to ensure contact with the bottom of the 
plate, the plate is incubated for 24h at 37°C 5% CO2. Five µl Nb dilutions or vehicle are added 
per well followed by short centrifugation of the plate and incubation for 1h at 37°C. Five µl 
of ephrina1 (1.2 µg/ml) or vehicle is added to each well followed by short centrifugation of 
the plate and incubation for 3h at room temperature. Twelve µl of detection reagent 
(Galacton Star, Emerald II solution, PathHunter cell assay buffer in relative volumes of 1:5:19 
respectively) is added followed by short centrifugation ensuring contact with media. After 
one hour incubation at room temperature the plate can be read on a Pherastar (BMG 
Labtech, Ortenberg, Germany). Percentage activity is calculated as (signal – positive control)/ 
(negative control– positive control)*100. The positive control is background without any 
ephrin added. The negative control is maximum signal with ephrin stimulation without any 
Nanobody added.   
 
AlphaScreen 
To test the specificity of the Nbs for the different Eph receptors all Nbs were biotinylated 
with a five times molar excess of EZ link NHS biotin (Thermo Scientific, Breda, Nederland, 
21217). The Nbs were incubated with the biotin for two hours on ice allowing the interaction 
of the biotin with the primary amines on the surface of the protein. Ten µl of biotinylated 
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Nbs (100 nM) were incubated with 10 µl of a subhooking concentration of mouse 
recombinant Eph receptor (R&D, Abingdon, UK, 641-A4-200) for one hour in standard buffer 
(50 mM Hepes, 100 mM NaCl, 0.1% Triton and 0.1% BSA). The determined subhooking 
concentrations are 3 nM for EphB4, 10 nM for EphA2, A4, B2 and B3, 30 nM for EphA3, A6, 
A7 and B6, and 100 nM for EphA8. Ten µl of anti-IgG AlphaLISA acceptor beads (20 µg/ml; 
Perkin Elmer, Zaventem, Belgium, AL103M and AL105M) and 10 µl streptavidin donor beads 
(20 µg/ml; Perkin Elmer, Zaventem, Belgium, 6760002) were subsequently incubated for one 
hour and 30 minutes respectively at room temperature, protected from light. The plate was 
read on the Envision Multilabel Reader (Perkin Elmer, Zaventem, Belgium). A Nanobody 
targeting the Superoxide Dismutase 1 protein (SOD1) was used as a negative control. 
 
To test the inhibition of interaction between EphA4 and its different ligands, the EphA4 LBD 
(2mg/ml) was biotinylated with a two and a half times molar excess of EZ link NHS biotin 
(Thermo Scientific, Breda, Nederland, 21217) for two hours on ice allowing the interaction of 
the biotin with primary amines on the surface of the protein. Five µl of a subhooking 
concentration of biotinylated EphA4 LBD (10 nM) was incubated with five µl of different 
concentrations of Nb for one hour in standard buffer (50 mM Hepes, 100 mM NaCl, 0.1% 
Triton and 0.1% BSA). Subsequently five µl of subhooking concentration of ephrin ligand was 
added and incubated for one hour at room temperature. The determined subhooking 
concentrations are 3 nM for efna1 and efna4, and 10 nM for efna2-3, efna5 and efnb1-3. 
Next five µl of anti-IgG AlphaLISA acceptor beads (20 µg/ml, Perkin Elmer, Zaventem, 
Belgium, AL103M and AL105M) and five µl streptavidin donor beads (10 µg/ml, Perkin Elmer, 
Zaventem, Belgium, 6760002) were added and incubated for one hour and 30 minutes 
respectively at room temperature, protected from light. The plate was read on the Envision 
Multilabel Reader (Perkin Elmer, Zaventem, Belgium). A Nanobody targeting the Superoxide 
Dismutase 1 protein (SOD1) was used as a negative control.   
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General discussion 
 
Epha4 plays an important role in embryonic development as an axonal guidance repellent 
151, 314. The role of Epha4 in the adult central nervous system has been addressed only 
recently. It has been found to play a role in synaptic plasticity, and has been implicated in 
the pathogenesis of several disorders such as cancer and several neurological disorders such 
as trauma, neuroinflammatory and neurodegenerative diseases 219, 221, 227. We have 
previously shown Epha4 to be a modifier of ALS, in animal models as well as in patients 35. 
Reduced Epha4 expression increased motor performance and survival of the SOD1G93A 
mouse model and EphA4 expression inversely correlated with disease severity in ALS 
patients. However, the mechanism through which Epha4 reduction/inhibition attenuated 
ALS pathogenesis is unclear. In this present work, we addressed several aspects of Epha4 
biology in ALS and developed Nanobodies against EphA4 as a tool for future mechanistic or 
therapeutic studies.   
 
 
Epha4 contributes to the vulnerability of motor neurons  and determines re-innervation 
capacity 
 
Epha4 is mainly expressed in motor neurons in the spinal cord of SOD1WT and SOD1G93A mice. 
We confirmed that large motor neurons are more vulnerable in ALS, and demonstrated that 
these are preferentially rescued when Epha4 is reduced. Thus, vulnerability and 
regeneration capacity seem to be somehow interrelated or may even be two characteristics 
a the same biological reality. Of interest, we showed that Epha4 at least partially determines 
sprouting capacity of motor neurons. Mice with decreased Epha4 expression showed a dose-
dependent improvement in neuromuscular junctions re-innervation after sciatic nerve injury 
35. This enhanced sprouting was also detected in rats after corticospinal tract injury when 
treated with an Epha4 antagonist 213. It is tempting to speculate that this is also reflected in 
what is well known to occur in the growth cone of embryonic motor neurons. Epha4 
expressed on the growth cone interacts with ephrin ligands on adjacent cells leading to the 
reorganization of the cytoskeleton through RhoGTPases and induces growth cone collapse 
212, 315-317. This sprouting capacity can be restored by treatment with Epha4 antagonists as 
shown by the rescue of the growth cone collapse in cultured neurons 213, 284.  
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Epha4 reverse signaling in the biology of ALS  
 
Interaction between Eph receptors and ephrin ligands can result in forward signaling in the 
Eph-bearing cell and reverse signaling in the ephrin-bearing cell. We found that partial 
replacement of Epha4 by an Epha4 molecule in which the cytoplasmic domain of Epha4 has 
been replaced by an eGFP cassette, did not influence ALS in the SOD1G93A mouse model. This 
indicates that it is the reverse signaling of Epha4 that is hazardous in ALS and explains the 
modifying effect of Epha4 in ALS. Some caution is needed for the interpretation of this 
observation. Indeed, in the Epha4 molecule, the entire intracellular domain is absent, which 
affects expression of the Epha4eGFP isoform, receptor clustering, and endocytosis. Thus, 
more than reverse signaling may be affected in this Epha4eGFP molecule. This is indeed 
evident from the axotomy experiments in which reduced regeneration was seen, indicating 
that the replacement of the intracellular domain with eGFP results in more than silencing 
the reverse signaling. Therefore, it may be of interest to repeat this experiment with a 
mouse in which the kinase activity is silenced through a point mutation rather than through 
the replacement of the entire domain. These experiments are being performed in the lab.  
In spite of these considerations, it can be concluded that reverse signaling at least partially 
contributes to the effect of Epha4 in ALS. This can occur through interaction with ephrin 
ligands on muscle cells, astrocytes, oligodendrocytes, microglial cells or motor neurons 
themselves (through cis interaction), as all these cells are known to express ligands for 
Epha4.  
 
 
Ephrins in ALS 
We quantified all ephrins in the spinal cord of the SOD1G93A mouse, and concentrated on 
astrocytic ephrins as no consistent pattern emerged. Ephrina2, ephrina3 and ephrinb2 are 
expressed on astrocytes 251-252. The role of ephrina2 in astrocytes has not yet been 
elucidated. Ephrina3 on the other hand is a crucial regulator of synaptic function and 
plasticity 205. Astrocytic ephrina3 is critical in the regulation of hippocampal dendritic spine 
morphology and it regulates the abundance of glial glutamate transporters which is crucial 
to prevent glutamate toxicity under pathological conditions 205, 253-255. Under normal 
physiological conditions, ephrinb2 signaling in astrocytes regulates adult hippocampal 
neurogenesis 252. After spinal cord injury, its expression is highly upregulated in the 
astrocytes of the glial scar after spinal cord lesions 256. Furthermore, the deletion of ephrinb2 
from reactive astrocytes reduced glial scar formation and improved recovery after spinal 
cord injury 256-257. This improved recovery was correlated with an increased regenerative 
capacity of sprouting spinal cord axons 212, 257. Ephrina5 has not been detected on resting 
astrocytes, but its expression is highly upregulated in astrocytes at the peri-lesioned area 
after experimental stroke 218. In this model, high astrocytic ephrina5 expression inhibited 
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axonal sprouting and motor recovery 218. Both ephrina5 and ephrinb2 are interesting 
interaction candidates of Epha4 in the pathogenesis of ALS, as their expression is 
upregulated in reactive astrocytes which is a hallmark of ALS. Here, we explored the role of 
ephrinb2 during ALS pathogenesis.  
 
 
Ephrinb2 in ALS 
In normal conditions, ephrinb2 is highly expressed in motor neurons. In ALS, the declined 
ephrinb2 expression due to motor neuron loss is accompanied by an obvious ephrinb2 
expression in reactive astrocytes, which may explain why total spinal cord levels barely 
change. Transgenically deleting ephrinb2 from the astrocytes worsened disease in the 
SOD1G93A mouse. Ephrinb2 therefore unlikely is involved in the Epha4 reverse signaling, 
which mediates the hazardous reverse signaling explaining the beneficial effect of Epha4 
inhibition. Two of our findings, likely to be related, may explain the hazardous effect of the 
deletion of ephrinb2 from the ALS mouse. First the expression of CX3CR1, a marker for CNS 
microglia and inflammatory cells from the circulation, was greatly increased, indicating 
increased inflammation in the spinal cord, which may enhance motor neuron degeneration. 
Second, we found evidence for disruption of the BBB upon deletion of ephrinb2 form 
astrocytes. The BBB consists of endothelial cells, pericytes and astrocytes creating a 
neurovascular unit with the adjacent neurons 318. Evidence for abnormalities of the BBB and 
BSCB has been found in animal models of ALS and in ALS patients 276, 319-320. Barrier 
impairment has even been detected in mutant SOD1 mice and rats before motor neuron 
degeneration and inflammation 277, 320. Reduction of tight junction proteins and swollen 
astrocyte-endfeet that dissociate from the endothelium has been found 273, 276, 321. We found 
that astrocyte-specific deletion of ephrinb2 worsened the BBB leakage in mutant SOD1 mice, 
an effect that became more pronounced when disease progressed. Further investigation is 
needed to investigate the role of astrocytic ephrinb2 on tight junction expression and the 
association of its astrocyte-endfeet with the endothelium, but already, our data suggest that 
alterations in the BBB and BSCB enhance motor neuron degeneration 276 and that 
understanding the BBB pathophysiology may implicate therapeutic options.  
Furthermore, the question arises which receptor astrocytic ephrinb2 interacts with to have 
its effect in ALS and on the BBB. Obvious candidates are EphB2 and EphB4 on endothelial 
cells, which have been studied extensively, especially during development 322-324. However, 
as VEGFR1 and VEGFR2 have been detected in astrocytes, it is also possible that ephrinb2 
interacts in cis with a VEGFR thereby regulating its internalization and signaling 262-263, 325-326. 
Of interest is the notion that ephrinb2 and VEGF have been shown to be very tightly linked 
during angiogenesis and lymphangiogenesis 263, 327. More specifically, ephrinb2 regulates the 
internalization and signaling of VEGFR2 and VEGFR3 262-263. VEGF is upstream of ephrinb2 
110 
 
and controls its expression 328-329. We have previously found that VEGF may be involved in 
the biology of ALS, as decreasing VEGF expression enhances ALS and treatment of ALS rats 
with VEGF attenuates their disease 330-331. Similarly astrocyte-specific deletion of ephrinb2 
worsened the disease progression, suggesting that reducing ephrinb2 levels might interfere 
with VEGF signaling at play in the astrocytes. However, further investigation is needed to 
elucidate whether reducing ephrinb2 levels in astrocytes impairs VEGFR internalization and 
VEGF signaling in this way contributing to the worsened disease progression. VEGF is 
neurotrophic factor and it protects motor neurons from insults such as glutamate-mediated 
excitotoxicity 332. However, VEGF might also affect motor neurons through an indirect effect 
on glial cells such as astrocytes. VEGF might influence the release of neurotrophic factors 
and they might protect motor neurons from excitotoxicity by inducing GluR2 expression 
and/or regulating glial glutamate transporter expression 333. Further investigation is needed 
to elucidate whether these mechanisms are at play in the worsened disease progression of 
efnb2fl/fl; Cx30; SOD1G93A mice.  
 
 
Developing a specific Epha4 inhibitor 
Blocking the EphA4 receptor attenuates motor neuron degeneration. However, EphA4 
antagonists have major shortcomings as discussed above. We therefore set out to develop 
better tools. As it is the reverse signaling, which likely underlies the effects of EphA4 in ALS, 
inhibitors of its forward (kinase-dependent) signaling, if specific ones could be generated, 
are less attractive. We therefore took the challenge of generating blockers of the 
extracellular, ligand-binding domain through the development of Nanobodies. So far, no 
conventional antibodies are available that target the EphA4 ligand-binding domain, most 
likely due to the dynamic nature of this domain 144, 146, 286. However, Nanobodies have been 
used to fix receptors in one conformation, thereby facilitating the development of crystal 
structures to determine its structure 293, 334. This property of Nbs is useful for the 
development of a Nb targeting a dynamic structure such as the EphA4 ligand-binding 
domain.  
From the fifteen Nbs initially identified in the screen, we found two Nanobodies (Nb 39 and 
Nb 53) with high affinity for EphA4. These Nbs were most selective for EphA4, though they 
also show binding to EphA7. Furthermore, they blocked the interaction with all ephrin 
ligands and inhibited ephrin-induced phosphorylation. Nb 39 and Nb 53 are at least 10 times 
more potent than the KYL-peptide. EphA7 has not as extensively been studied as EphA4, but 
similar results as EphA4 have been shown in spinal cord injury 305, 335. This suggests that 
blocking both EphA4 and EphA7 might result in an even better outcome. However, this will 
need further investigation.  
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Among existing EphA4 antagonists, both Nb39 and 53 are good inhibitors with KD values in 
the high nanomolar range. However, most Nanobodies published so far have KD values in the 
low nanomolar, even picomolar range 336. The affinity of these Nbs can be further increased 
through error-prone PCR mutagenesis and/or making bispecific Nbs 312-313. Nbs are easily 
engineered into multivalent and multispecific formats 312. Bivalent or bispecic Nbs can be 
obtained by connecting two identical or two different Nbs with a linker thereby improving 
the avidity. However, dimerisation of Eph receptors induces clustering and subsequently 
activation, which can be obtained with a preclustered antibody 337. Therefore we have to be 
cautious how to design multivalent Nbs. As linking two Nbs targeting the ligand-binding 
domain is likely to induce clustering, another option would be to link a Nb targeting the 
ligand-binding domain with a second Nb targeting another region of the EphA4 extracellular 
domain. However, further investigation is needed to elucidate which would be the best 
option.  
Overall, further studies are needed to investigate whether the promising results of the can 
be translated in in vitro and in vivo functional models. We will investigate whether Nb 39 and 
53 are able to rescue ephrin-induced growth cone collapse, which has been shown for 
known EphA4 antagonists 213, 284. The best Nb will be tested in in vivo functional models. As 
EphA4 plays a role in acute injuries as well as in neurodegenerative disorders, the usefulness 
of the Nb can be tested in different models.   
 
Future perspectives 
We have previously shown Epha4 to be a modifier of ALS in animal models and in patients. 
We tried to unravel the mechanism of action of the hazardous effect of EphA4 in ALS. We 
found Epha4 to contribute to the vulnerability of motor neurons in the SOD1G93A mouse 
model. Future experiments are needed to elucidate whether this also holds true in ALS 
patients. Next to vulnerability, we also investigated the role of the signaling direction of the 
ephrin system in ALS. Experiments with the Epha4eGFP/eGFP mouse model showed that Epha4 
reverse signaling at least partially contributes to the hazardous effect of Epha4 in ALS. 
However, as as we have to be cautious when interpreting these results, we are currently 
repeating this experiments with a mouse in which the kinase activity is silenced through a 
point mutation rather than through the replacement of an entire domain. Comparing all 
results together will give us more insight in the complex signaling of the ephrin system and 
which signaling contributes to the hazardous effect of Epha4 in ALS.  
 
 
Epha4 interacts with different ephrin ligands. In this PhD thesis we focused on the role of 
ephrinb2 in the pathogenesis of ALS. We found reduction of astrocytic ephrinb2 to have a 
detrimental role in ALS pathogenesis. Further research is currently being performed in our 
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laboratory to elucidate the mechanism of action. As ephrinb2 is not likely to be the 
interaction partner of Epha4 in its hazardous effect on ALS, the role of another ephrin 
ligands will be investigated. Recent data in our laboratory showed ephrina5 to be 
upregulated in reactive astrocytes (data not shown). We are currently elucidating the role of 
ephrina5 in the pathogenesis of ALS.  
We also explored the therapeutic potential of EphA4 inhibitors in the pathogenesis of ALS. 
We found C1 to be chemically unstable thereby limiting its potential for in vivo use. We are 
currently testing the therapeutic potential of new EphA4 inhibitors such as APY-βAla8.am in 
the pathogenesis of ALS. In addition, we tried to develop specific EphA4 inhibitors using 
Nanobody technology. We found two Nanobodies, Nb 39 and Nb 53 to be good EphA4 
inhibitors. Future experiments are needed to investigate its therapeutic potential both in 
vitro and in vivo in the pathogenesis of ALS. In addition, we will try to improve the specificity 
and affinity of Nb39 and 53.  
  
EphA4 as therapeutic target? 
In this first part of PhD thesis we tried to unravel the mechanism of action of EphA4 in the 
pathogenesis of ALS. Using different transgenic mouse models, we revealed new aspects of 
the ephrin system on a molecular level. However, the experiments with these mouse models 
showed that we have to be cautious when interpreting these results. Influencing the system 
has led to surprising results, showing again the complexity of this system. The hazardous 
effect of Epha4 has also been shown in other neurological disorders, but the mechanism of 
action and the best way to target EphA4 awaits further investigation and could vary between 
different disorders.  
In the second part of this PhD thesis we explored the therapeutic potential of EphA4 
inhibitors of ALS and developed new EphA4 inhibitors using Nanobody technology. Several 
EphA4 inhibitors have been developed, but many of them have major shortcomings as 
discussed above. Improved inhibitors have been developed (Nb 39 and Nb 53, APY-
βAla8.am), but further refinement is needed to increase its affinity, selectivity and 
pharmacokinetic properties. In addition, EphA4 inhibitors must be able to reach their target 
which is prevented by the BBB. In acute injuries this barrier is impaired, but in 
neurodegenerative diseases such as ALS getting drugs across the BBB still remains a major 
challenge.  
To conclude, improvements in EphA4 inhibitors and unraveling the ephrin system might 
open new possibilities to treat several neurological disorders.  
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Summary 
 
Amyotrophic Lateral Sclerosis (ALS) is a dramatic neurodegenerative disease due to its 
progressive character, the short survival of the patient and the enormous impact on his/her 
quality of life and that of his/her caretaker. Interestingly, ALS patients, even carrying the 
same mutation in SOD1, have great variations in clinical characteristics as age of onset, 
disease duration and severity of the disease. This indicates that ALS is a multifactorial 
disease influenced by modifying genes and environmental factors. Epha4 is such a genetic 
factor that modifies ALS both in animal models as well as in patients. We investigated the 
mechanism in which Epha4 is modifying the disease pathogenesis in ALS. We found that 
vulnerable motor neurons have high Epha4 expression and that Epha4 reduced the re-
innervating capacity of motor neurons, possibly contributing to the higher vulnerability of 
Epha4 expressing motor neurons in ALS. Furthermore, deleting the Epha4 cytoplasmic 
domain did not affect disease onset and survival in the SOD1G93A mouse model indicating 
that Epha4 forward signaling in the Eph-bearing cell does not play a role in the modifying 
effect of Epha4 in ALS. We therefore suggest that the reverse pathway in the ephrin-bearing 
cell should be modified in order to alter ALS pathology. We studied ephrinb2 as a possible 
ligand for the Epha4-mediated effect in ALS. It was highly expressed in motor neurons and in 
reactive astrocytes. However, deletion of ephrinb2 enhanced disease rather than 
attenuating it. Interestingly, deleting ephrinb2 from the astrocytes impaired the blood brain 
barrier integrity which possibly contributed to the reduced disease duration and survival in 
the SOD1G93A mouse model.  
To inhibit Epha4 reverse signaling we developed Nanobodies targeting the EphA4 ligand-
binding domain. Nb 39 and Nb 53 were selective for EphA4, and had KD and IC50 values in the 
nanomolar range. Both Nanobodies were able to block the interaction of EphA4 with all 
ephrin ligands and they inhibited ephrin-induced phosphorylation. In conclusion, blocking 
the interaction of EphA4 and its ephrin ligands will be the most efficient way to block EphA4 
reverse signaling and to develop a specific EphA4 antagonist.  
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Samenvatting 
 
Amyotrofe Laterale Sclerose (ALS) is een dramatische neurodegeneratieve aandoening door 
het progressieve karakter van de ziekte, de korte overleving van de patiënt en de grote 
impact op zijn levenskwaliteit en die van zijn omgeving. ALS-patiënten met dezelfde mutatie 
in SOD1 vertonen grote variabiliteit in klinische manifestatie van de ziekte zoals de leeftijd 
waarop de eerste symptomen voorkomen, de ziekteprogressie en de agressiviteit waarmee 
de ziekte evolueert. Dit toont aan dat ALS een multifactoriële ziekte is die beïnvloed wordt 
door modificerende genen en omgevingsfactoren. Epha4 is zo’n genetische factor die de 
ziekte beïnvloedt zowel in diermodellen als bij patiënten. We onderzochten het mechanisme 
van Epha4 dat het verloop van de ziekte beïnvloedt. Hoge Epha4-expressie verminderde het 
reïnnervatiepotentieel van grote motorneuronen, wat bijdraagt aan de hogere gevoeligheid 
van deze motorneuronen in ALS. Bovendien had de verwijdering van het intracellulaire 
domein van Epha4 geen invloed op het tijdstip van aanvang van de ziekte en de overleving 
van de SOD1G93A muis, wat er op duidt dat de voorwaartse signalisatie in de cel die EphA4 
bevat, geen rol speelt in het modificerende effect van Epha4 in ALS. Dit suggereert dat er 
geïnterfereerd moet worden met de terugwaartse signalisatie in de cel met de 
efrineliganden om de ziekte te beïnvloeden. Efrineb2, één van de Epha4-liganden, was 
duidelijk aanwezig in motorneuronen en reactieve astrocyten. Het verwijderen van efrineb2 
van de astrocyten tastte de bloedhersenbarrière aan, wat onder meer zorgde voor een 
verminderde duur van de ziekte in de SOD1G93A muis. Om de terugwaartse signalisatie van 
EphA4 te blokkeren, ontwikkelden we Nanobodies gericht tegen het ligand-bindende 
domein van EphA4. Nanobody 39 en 53 interageerden selectief met EphA4 en hadden KD en 
IC50 waardes in het nanomolaire bereik. Beide Nanobodies konden de interactie van EphA4 
met alle efrineliganden blokkeren en inhibeerden EphA4-fosforylatie geïnduceerd door 
efrinea1. Dit werk toont aan dat het blokkeren van de interactie tussen EphA4 en zijn 
efrineliganden de meest efficiënte manier zal zijn om de terugwaartse signalisatie van EphA4 
te blokkeren en om een specifieke EphA4-inhibitor te ontwikkelen.  
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